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ABSTRACT OF DISSERTATION 
Neuropeptidases are responsible for degradation of signaling peptides in the 
central nervous system and periphery.  Some neuropeptidases have also been shown to 
play a role as part of the cell’s hydrolytic machinery responsible for breaking down 
proteins and peptides into amino acids, and these enzymes therefore influence small 
peptide availability for antigen presentation.  A better understanding of how 
neuropeptidases recognize their substrates could lead to therapeutics that modulate the 
activity of these important enzymes.  Alternatively, re-engineering these enzymes to 
selectively hydrolyze undesirable peptides could make them attractive as therapeutics 
themselves.  A key question in understanding the activity of these enzymes is how they 
are able to recognize a variety of seemingly unrelated amino acid sequences as cleavage 
sites.  We are investigating the basis for this general substrate recognition in 
neuropeptidases using thimet oligopeptidase (TOP) as a model.  Crystal structures of 
TOP in complex with a variety of substrates and inhibitors shed light on the mechanisms 
underlying substrate recognition and pave the way for re-targeting substrate recognition 
in these enzymes. 
Nano test tube particles have been proposed as a means of delivering therapeutics 
such as enzymes.  However, the template synthesis method for nano test tube production 
does not produce therapeutic quantities.  In order to take full advantage of re-engineered 
neuropeptidases a new method for nano test tube synthesis has been developed.  We 
show that a non-destructive template synthesis methodology can be applied to produce 
nano test tube particles in quantities useful for therapeutic enzyme immobilization.  
 
Keywords:  Neuropeptidase, substrate recognition, X-ray crystallography, template 
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CHAPTER ONE:  Introduction 
How neuropeptidases effect cell signaling  
 One of the most common signaling molecules used by cells to communicate are 
small peptides.  In eukaryotes, these peptides are initially produced in a highly regulated 
fashion as preprohormones and subsequently processed by endolytic enzymes into their 
smaller, active forms [1].  The paracrine, autocrine, or endocrine peptide signal is 
communicated by release of the peptides into the extracellular region where it can be 
carried to specific cell surface receptors (Figure 1.1).  Termination of the peptide signal is 
brought about by hydrolytic peptidases in the extracellular matrix or cytosol.  The 
duration of a given peptide signal is therefore dependent, in part, on how quickly it is 
degraded after release.  The peptidases responsible for biopeptide metabolism have been 
the target of extensive research in academia as well as the pharmaceuticals industry and 
there are a number of examples of peptidase targeted drugs [2, 3]. 
 Bioactive peptides are often termed neuropeptides, and the hydrolytic enzymes 
that metabolize them are called neuropeptidases.  One of the largest classes of 
neuropeptidases are the soluble metalloendopeptidases [1].  Of these angiotensin 
converting enzyme (ACE) is probably the most well known since its inhibition lowers 
blood pressure and prevents heart attack [4, 5].  Two other metalloendopeptidases closely 
related to ACE, thimet oligopeptidase (TOP) and neurolysin, have also been studied 
extensively for their roles in many physiological processes.  These two enzymes have 
been implicated in nociception [6-9], blood pressure regulation [10-13], the immune 
system [14-16], reproduction[1, 17], tumorigenisis [18], and plaques associated with 
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Alzheimer’s disease [19].  In an effort to control these two enzymes, relatively selective 
competitive inhibitors have been developed [20-22], but they are not currently the targets 
of any disease therapy. 
Roles of thimet oligopeptidase and neurolysin. 
TOP and neurolysin are 63% identical in primary sequence and share very similar 
folds [23].  These two similar enzymes were first isolated from brain tissue based on their 
ability to hydrolyze the important neurotransmitter neurotensin [8, 24].  Later they were 
differentiated by their differing neurotensin cleavage sites [25].  The difference in 
neurotensin cleavage site can be attributed to just two sequence changes at residues 
located in the large central channel that runs the length of the enzyme, which also 
contains the active site [23].  Specific TOP and neurolysin inhibitors were shown to 
prevent bradykinin hydrolysis resulting in lower blood pressure and increased vascular 
permeability [11, 13, 26].  Similarly, inhibitor studies showed a potentiation of opioid 
mediated anti-nociception indicating involvement of TOP and/or neurolysin in 
degradation of opioid peptides such as adrenorphin, dynorphin A, and dynorphin B [7].   
Degradation of the important reproductive hormone luteinizing hormone releasing 
hormone (LHRH) by TOP coupled with prolyl oligopeptidase [17, 27-29] was also 
demonstrated in vitro and in vivo using inhibitors.  Degradation of signaling peptides by 
TOP and neurolysin often have the effect of inactivating them, however, many products 
of degradation have physiological effects of their own.  Liberation of enkephalins from 
dynorphin A(1-8) and adrenorphin [30] and LHRH 1-5 from LHRH [27], for example.  
The important roles played by TOP and neurolysin in controlling the levels of bioactive 
3 
 
peptides has made inhibitor development targeting these enzymes an area of active 
research [31-33]. 
Roles for TOP and neurolysin in the immune system 
 The proteasome constantly recycles proteins in the cytosol of the cell by 
hydrolyzing them into peptide fragments.  This population of fragments containing 
largely oligopeptides 4-24 residues long with basic, hydrophobic, and acidic amino acids 
at their C-termini [34] is the pool from which, ultimately, TAP and MHC I are loaded 
with antigenic epitopes for presentation to scanning immune cells at the cell surface [35].  
MHC I epitopes taken from proteasomal products are trimmed at the N-termini by 
cytosolic peptidases, but usually retain their original C-termini residues up to the point 
where they are presented by MHC I (Figure 1.2). 
 One of the best studied examples of broad peptide recognition comes from the 
MHC class I and class II proteins of the immune system, which present processed 
peptides to T cell receptors on the surfaces of lymphocytes to activate immune responses 
[36].  Interestingly, some aspects of the broad recognition mechanism found in TOP are 
also used by the MHC molecules.  In both types of MHC molecules, peptides bind in 
narrow clefts defined by two parallel but somewhat separated helices.  MHC class I 
molecules achieve broad peptide binding by interacting primarily with the N and C 
termini of bound ligands as they associate with the binding groove [37, 38].  As noted, 
TOP makes extensive interactions with the C-termini of bound peptides, and like MHC I, 
basic and aromatic residues are involved in the interactions.  The binding sites of both 
types of MHC molecules are rich in aromatic residues, like the TOP binding surface.  
Like peptides on the TOP binding surface, peptides bound to MHC I follow variable 
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paths in interacting with the surfaces of the groove walls [39], although the degree of 
contact between the peptides and either wall surface are not as extensive as the 
interaction with the binding surface in TOP.  MHC II molecules interact with a broad 
range of peptides by making a number of hydrogen bonds to groups on the peptide 
backbone, again reminiscent of the backbone hydrogen bonds made to the TOP binding 
surface [36, 40].  In contrast to TOP, though, peptides binding to MHC II uniformly 
adopt a polyproline II type helical backbone conformation, having the effect of precisely 
placing backbone groups in position for hydrogen bond interactions with the protein [40].  
The relatively flat surface in TOP allows considerably more variability in the backbone 
conformations of bound peptides.  The interaction with the binding groove of MHC does 
bury more of the accessible peptide surface than binding to the flat surface of TOP [41].  
Furthermore, groove closure appears to reduce the off rate of the peptide from MHC by 
physically entrapping it [42].  Overall, these led to more extensive interactions with the 
peptides, consistent with the much higher affinity shown by the MHC molecules.  This 
high affinity would not be desirable in TOP, which must release product peptides to turn 
over catalytically. 
Broad substrate selection by TOP and neurolysin 
TOP and neurolysin are active only on relatively short peptide substrates.  The 
longest reported substrate is 17 residues in length [43].  They generally hydrolyze 
bioactive peptides preferentially at only one or two peptide bonds, and they cleave at sites 
with significant sequence variations (Figure 1.3).  The only generalization that can be 
made is that TOP substrates tend to be somewhat enriched in hydrophobic, aromatic, and 
basic residues, but these can occur at different positions relative to the cleaved bond.  
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This trend also reflects a bias in the residue composition of bioactive peptides, and may 
therefore not be of particular significance in TOP substrate recognition.  Some studies 
have characterized TOP specificity through degradation kinetics of various sequences 
[43-45], however, no definitive structural evidence is available to show the extent of the 
TOP binding surface or the type of interactions that produce its fuzzy specificity.  TOP’s 
ability to hydrolyze specific bonds inside substrates with no apparent sequence similarity 
– an attribute which is shared by most other neuropeptidases allows it to be used to 
metabolize different bioactive peptides in different cell types and different subcellular 
locations.  The structural basis for this “fuzzy” substrate recognition is an important 
question in molecular recognition and is of fundamental importance to predicting or 
manipulating TOP specificity. 
Previous insights from thimet oligopeptidase structures 
 TOP and neurolysin are members of the thermolysin-like zinc metallopeptidase 
family that contain the active site amino acid sequence motif HEXXH [46].  The 
sequence forms part of a helical element, and the two histidines can coordinate a zinc ion 
cofactor with the help of a downstream glutamate.  The glutamate in the sequence motif 
orients and activates a water molecule for nucleophilic attack on the carbon of peptide 
main chain carbonyl groups to affect hydrolysis of the peptide bond. The zinc ion 
cofactor promotes deprotonation of the attacking water group and stabilizes charge 
development on the carbonyl oxygen in the transition state.  Studies using inhibitors to 
model substrate binding indicate that polypeptide substrates interact with the edge strand 
of a beta sheet located at the active site, forming main chain hydrogen bonds to 
effectively extend the sheet by an additional, anti-parallel strand [47].  The HEXXH 
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motif was first characterized structurally in the bacterial protease thermolysin [48], where 
the helix is located near the center of a slightly concave surface of the enzyme.  Initial X-
ray structures of much larger TOP and neurolysin [49, 50] revealed that these enzymes 
have a much deeper channel running the length of the molecule, with the active site 
located near the base of one channel wall. The overall fold then is clam-shell shaped 
(Figure 1.5).  With this architecture, only peptides in an extended conformation can 
diffuse into the central channel and gain access to the active site machinery, explaining 
the lack of activity on larger peptides and proteins.  
 Other metalloendopeptidases including dipeptidyl carboxypeptidase (DCP) [51] 
and angiotensin converting enzyme 2 (ACE2) [52] have been solved in the closed ligand-
bound form as well as the open, unliganded form (Figure 1.6).  The structure of DCP 
provides a particularly close analogy to what closed, substrate-bound, TOP might look 
like.  This structure was solved in complex with two dipeptide fragments interacting with 
DCP near the active site.  One fragment binds forming anti parallel beta sheet-like 
interactions next to the active site with additional interactions being donated from the 
opposite side of the cleft.  Another fragment binds at a different angle that carries it away 
from the active site to interact with the second domain.  Based on DCP we would expect 
TOP to undergo a similar hinge-like bending motion that narrows the central channel.  
This conformational change would likely be stabilized by the presence of a bound peptide 
interacting with both channel walls. 
 In the closed form of DCP, the central channel is too narrow to allow peptide 
diffusion into the active site, and the initial interaction of substrate peptides must be with 
the open form of the enzyme.  It is not clear how these initial interactions occur.  Work 
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presented in this dissertation describes and characterizes an initial substrate binding 
surface present in TOP.  The results also define a mechanistic basis for the broad 
substrate recognition shown by TOP and a number of other neuropeptidases.  Ultimately, 
this work should allow for rational alteration of the substrate binding specificity of TOP, 
neurolysin, and similar oligopeptidases.  And put together with thermodynamic and 
biochemical experiments these structures contribute to our understanding of protein-
peptide interactions as a whole. 
Neuropeptidases as therapeutics 
 Most current therapeutics are small molecules that target macromolecules in the 
body.  A promising, but considerably less developed, alternative is to use 
macromolecules themselves as therapeutics.  Macromolecules have the potential for 
complex effects that can never be mimicked by small molecule drugs [53, 54].  Indeed, 
one of the fastest growing category of FDA approved drugs are biological polymers [55].  
Enzymes in particular have a bright future since they can catalyze desired biological 
reactions over an extended period.  Moreover, modern molecular biology provides the 
means for large scale recombinant enzyme production and even control over enzyme 
specificity using mutagenesis.  
 Especially notable success using enzymes has already been achieved for diseases 
caused by the complete lack of an enzyme, such as lysosomal storage diseases, where 
enzyme replacement therapy is the standard of care [53, 56-58].  However, these enzyme 
therapies are expensive, require frequent dosing, and suffer from immune reactions [59, 
60].  New strategies for delivering enzymes are needed in order for these therapies to 
reach their full potential. 
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 Oligoendopeptidases such as TOP are attractive enzyme therapeutics because they 
can degrade numerous undesirable bioactive peptides such as beta amyloid and 
angiotensins.  Also, since they do not hydrolyze proteins, oligoendopeptidases are safer 
to use in the body relative to proteases.  Therefore, recombinant TOP with re-engineered 
specificity for only undesirable peptides instead of its natural, broad, specificity could be 
used as a therapeutic.  The principle of neuropeptidases as therapeutics has been 
demonstrated by expressing another neuropeptidase, neprilysin, peripherally in mouse 
models of Alzheimer’s disease [61, 62].  These treatments proved the concept of using 
neuropeptidases as therapeutics, however, they required the use of gene therapy - an 
approach with many disadvantages [63].  If similar levels of sustained peptidase activity 
could be achieved in vivo by simply injecting recombinant protein it would provide an 
attractive alternative.   
Nanoparticles for enzyme delivery. 
  Using molecular biology to retarget enzyme therapeutics is only one technique 
for improving efficacy.  Yet another major factor preventing the realization of enzyme 
therapy’s full potential is that the harsh environment of the body quickly inactivates most 
recombinant enzyme therapeutics [53, 64].  Consequently there has been great interest in 
vehicles for enzyme delivery that might allow therapeutic enzymes to function in a better 
environment.  Many groups have demonstrated the benefits of enzyme immobilization in 
or on nanoparticles [65-72].  Not only do nanoparticles allow stabilization of 
immobilized enzymes, but they also allow targeting of enzyme therapeutics to specific 
organs or tissues [73-76].  Enzyme immobilization on nanoparticles is a promising route 
to improve efficacy of current enzyme replacement therapies [64, 68, 77] or to extend the 
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range of diseases that could feasibly be treated by enzyme therapy to include diseases 
such as cancer [78, 79], and Mitochondrial Neurogastrointestinal Encephalomyopathy 
(MNGIE) [64].   
 Most enzyme immobilization in nanoparticles has been done by attaching 
enzymes to the outside surface of solid, spherical, particles composed of a metal or 
polymer.  This is because spherical particles are the simplest to synthesize, however, 
elongated or tube shaped particles provide distinct advantages such as longer circulation 
time and larger payloads [80-82].  Furthermore, hollow particles that encapsulate 
enzymes within to create a “bioreactor” provide more protection from proteolytic 
degradation and immune system recognition [64, 68].  We envisioned a hollow, tube 
shaped, bioreactor that would safeguard enzymes inside while allowing free diffusion of 
substrates and products.  In addition to enzyme immobilization on the inside surface these 
tubes could be decorated with passivating or targeting functionalities on the outside.   
 Many different core-shell compositions are possible for template synthesized 
tubes including a wide variety of metals and biodegradable polymers [83-85].  Although 
template synthesis allows considerable control over nano tube parameters, current 
methods are limited in scale up for high volume manufacturing.  Porous alumina 
templates of suitably uniform pore size and appropriate length are not commercially 
available.  Synthesizing the templates is laborious and includes depositing thick layers of 
metal followed by long anodization in acid [86].  Once the desired materials are 
infiltrated, the alumina template is dissolved with strong etchants [84, 87], which are 
incompatible with many desired tube materials.  Destroying the template means re-
making a new template for every round of production.  The template synthesis method is 
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essentially a 2-dimensional synthesis, requiring large amounts of surface area (~20 m2) to 
produce commercial quantities.  Therefore, the resources and labor that would be 
required to manufacture therapeutic quantities of nano test tubes is prohibitive. 
Studies presented in this thesis. 
 In this work we set out to use structural and biophysical techniques to define the 
mechanism of fuzzy substrate recognition in thimet oligopeptidase (TOP).  This ability to 
recognize many different peptide sequences while retaining a degree of specificity is 
central to the function of this important class of enzymes. It is also a fundamental 
question in molecular recognition between biological molecules and bears upon the 
general problems of ligand and protein-protein recognition. In a more practical sense, we 
anticipate that understanding substrate recognition in these enzymes will enable the re-
engineering of TOP and similar neuropeptidases to modulate their degree of specificity, 
making them more suitable as therapeutics.  Similarly, understanding TOP substrate 
recognition may aid in the design of competitive TOP inhibitors.  Using X-ray 
crystallography we have succeeded in characterizing the interactions formed by a diverse 
set of peptide substrates upon initial binding to TOP.  These structures, coupled with 
biochemical and biophysical experiments, shed new light on the set of interactions 
available to TOP and reveal the extent of the TOP binding site.   
 Studies are also presented aimed at developing an approach for nanoparticle 
fabrication and enzyme immobilization that may allow TOP and other enzymes to be 
used in the clinic.  This work will advance the current field of enzyme therapeutics and 
provide the underpinnings for a new class of nanoparticle therapeutics.  By introducing a 
new technique for non-destructive template replication [88, 89] to quickly and easily 
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synthesize test tube shaped nanoparticles, we show that it is possible to scale up 
production to the level needed for industrial or therapeutic enzyme delivery.  In this new 
approach, the pores of a hard template are used to produce pillar like structures in a 
polymer material, which can subsequently be coated to make the nano tubes without 
alteration of the original template.   
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 Figure 1.1  Neuropeptide signaling.  Neuropeptidases hydrolyze signaling peptides at 
the cell membrane or within the cell.  In this way they can reduce the duration of a signal 
or trim peptides into smaller pieces with new signaling effects.   
 
 
  
 
13 
 
 
Figure 1.2  Antigen processing.  TOP degrades small cytosolic peptides that otherwise 
might be selected for presentation on major histocompatibility complex I (MHC I). 
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Figure 1.3  Preferred TOP cleavage sites.  TOP hydrolyzes substrates with a wide 
variety of amino acids near the cleaved bond. 
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Figure 1.4  Mechanism of hydrolysis.  Relevant TOP residues are shown as white 
sticks.  A generic peptide bond is shown in orange sticks.  a) The catalytic water 
molecule (purple sphere) coordinates zinc (yellow sphere) and is oriented / activated for 
nucleophilic attack by a nearby glutamate (E474).  E474 accepts a proton from the water 
during formation of the transition state.  b) The newly formed C-terminus coordinates 
zinc and E474 now donates a proton to the newly formed N-terminus.  Green arrows 
indicate that fragments are now free to diffuse away. 
 
 
 
 
 
 
a)  
 
 
b)  
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Figure 1.5  Clam shell shape of TOP.  Unliganded TOP structure cutaway at the level 
of the active site.  The active site coordinates a zinc ion (yellow sphere) near the bottom 
of a large interdomain cleft that limits substrate access.  TOP and neurolysin both share 
this fold. 
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Figure 1.6  Substrate induced closure of ACE2.  a) ACE2 unliganded structure 
cutaway at the level of the active site.  Zinc ion is shown as a yellow sphere b) ACE2 
after binding ligand (lisinopril) undergoes a significant closing motion. 
 
 
 
 
 
 
 
 
 
Copyright © Jonathan Wagner 2012 
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CHAPTER TWO:  Materials and Methods 
Thimet oligopeptidase 
Expression / purification of N truncated TOP 
 A TOP overexpession construct (residues 16-689) in the pET32a vector 
previously made in the lab [49] was used to produce the enzyme in E. coli.  In this 
construct, three cysteine residues are mutated to serine (C253S, C246S, C427S) to 
prevent covalent aggregation, and the catalytic glutamate residue is mutated (E474A) to 
greatly reduce activity.  Overexpression was carried out as previously described [49], 
with the exceptions that TB media was substituted for LB media and cultures were grown 
to an OD600 of 2.5 prior to being induced with 1 mM IPTG.  E. Coli were harvested four 
hours after induction, resuspended in 50 mM NaH2PO4 pH 8.0 with 1 mM BME and 20% 
glycerol, then frozen for later use. 
 TOP was purified by Ni affinity chromatography making use of the N-terminal 
polyhistidine fusion sequence in the expressed construct as previously described [49].  
Removal of the polyhistidine sequence by enterokinase cleavage was used to elute the 
enzyme from the affinity resin. TOP preparations typically yielded 25 mg protein per 
liter.  This protein was further purified by anion exchange chromatography using HQ 
Poros (Pharmacia) or Hyper D (Acrosep) strong anion exchange resins in an Akta FPLC 
system.  Conditions during anion exchange were 20 mM Tris pH 8.5, 10 mM NaCl, 2 
mM BME (binding) or with 1 M NaCl added (elution).  TOP was eluted from the 
columns using a gradient of 15 column volumes going to a final 15% elution buffer 
concentration.  This produced two closely associated protein peaks, mass spectrometry 
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revealed that the first peak was slightly lighter than the expected 77,906.5 Da molecular 
weight and the second was slightly heavier (peak 1 = 77,900 Da and peak 2 = 77,924 
Da).  Both peaks were similarly active in quenched fluorescent peptide degradation 
assays, but excluding peak two fractions allowed crystals to be produced more 
consistently.  The second peak was therefore usually discarded.  After elimination of 
peak 2 final yields were typically 15 mg of TOP per liter. 
Mutation and expression/purification of dual truncated TOP 
 N- and C-terminally truncated TOP constructs were made by using Quikchange 
mutagenesis to change either Gly680 or Glu684 of N-terminally truncated TOP to a stop 
codon.  The same primers were used to add stop codons at the same position to the 
Glu474A inactive as well as the Glu474 active version of TOP (Figure 2.1).  The four 
resulting sequences were confirmed by DNA sequencing.  
 Dual-truncated TOP was successfully expressed and purified using the same 
protocol as with purification of N truncated TOP.  Tryptic digest mass spectrometry was 
used to sequence dual truncated TOP and confirmed the expected serine 16 through 
valine 679 TOP sequence plus a cloning artifact comprising six additional amino acids 
(MADIGS) left on the N terminal after enterokinase digestion.  The total molecular 
weight of N15_C10_E474A _C246S_C253S_C427S TOP was 76,906.4 Da according to 
trypsin digest mass spectrometry (Figure 2.2), and this agreed perfectly with the 
calculated mass.   
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Activity of dual truncated TOP 
 The activity of dual truncated TOP ending with Val679 was compared to that of 
N-truncated TOP ending in Cys689.  Reaction buffer was 50 mM HEPES pH 7.2, 100 
mM NaCl, and 1 mM BME in a final reaction volume of 3 ml.  Quenched fluorescent 
neurotensin (Abz-NT-edd) [90] was added to a final concentration of 30 µM.  Then TOP 
was added to a final concentration of 10 nM and fluorescent readings taken starting 
immediately.  Activity was measured in a 1 cm disposable cuvette using a Perkin Elmer 
LS 55 Luminescence Spectrometer with the following settings: stir = on, photomultiplier 
= std @ setting 775, 2.5 nm slits, excitation = 319 nm, emission = 419 nm, temperature = 
37 oC. 
Crystallization of N truncated TOP 
 N truncated TOP was crystallized as reported before [49].  Briefly, 1 µl of TOP 
concentrated to 8-15 mg/ml in 20 mM Tris buffer pH 8.5, 10 mM NaCl, 2 mM BME, was 
mixed with 1 µl well solution and crystallized by hanging drop vapor diffusion at room 
temperature.  Well conditions were 0.1 M sodium cocadylate pH 6.5, 55 mM magnesium 
acetate, 11-13% PEG 6000.  Crystals grew to maturity in less than a day, sometimes even 
becoming visible within 30 minutes (Figure 2.3).  N-truncated TOP crystals were stable 
in solution even without precipitates, however, some crystals were unstable if harvested 
less than a day after crystallization.   
Crystallization of dual truncated TOP 
 Dual-truncated TOP altered either at Gly680 or Glu684 no longer crystallized in 
the conditions used for N-truncated TOP.  So, for crystallization the truncated TOP 
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construct ending at Val679 was transferred to a new buffer made up of 10 mM Tris pH 
8.5, 10 mM NaCl, and 2 mM BME.  Final concentration for crystallization was 3.0 - 5.0 
mg/ml TOP.  JCSG (Qiagen) suite crystallization screens (core suites I, II, III, IV) and 
subsequent condition optimization screens were set up in 96-well plates using a Mosquito 
automated crystallization robot (TTP Lab Tech) and the hanging drop vapor diffusion 
method.   Final optimized conditions were set up by hand in Greiner 24 well hanging 
drop plates.  Optimal well conditions were 100 mM CHES pH 8.3, 400 mM MgCl2, 12-
15% PEG 6000 and drops contained 3 uL protein solution to 1 uL well solution ratio.  
Plates were incubated at 12oC and long, board-like, crystals formed over 1-2 days (Figure 
2.3b). 
 A second condition also yielded dual-truncated TOP crystals that diffracted to 
below 2 Angstroms.  These crystals were grown from protein concentrated to ~6 mg/ml 
in the same 10 mM Tris pH 8.5, 10 mM NaCl, 2 mM BME buffer, but the well solution 
was 100 mM Tris pH 9.8, 450 mM MgCl2, 14-19% PEG 6000.  Drops contained 1 uL 
protein and 1 uL well solution.  These crystals were of a similar morphology and space 
group and yielded identical structures as in 100 mM CHES based conditions.  However, 
crystals grown from CHES conditions were preferred because of the more physiological 
pH and because CHES does not react with glutaraldehyde thus allowing crystals to be 
crosslinked in their mother liquor. 
Crystal soaking for complex formation 
 N-truncated TOP crystals were transferred to ligand solutions without any pre-
treatment.  Dual-truncated TOP crystals dissolved in dilute solutions.  Therefore they 
were stabilized using glutaraldehyde prior to ligand soaking.  Glutaraldehyde (25% from 
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Sigma) was diluted to 0.1% in crystallization well solution.  Crystals were removed from 
their mother liquor and held under the surface of a droplet of the 0.1% glutaraldehyde 
solution for 5-10 seconds.  (Glutaraldehyde in various polymeric sizes reacts with lysines 
by forming a Schiff base [91] and has been used before for stabilization of fragile crystals 
for cryocrystallography [92].)  Our aim was to crosslink crystals as lightly as possible to 
prevent protein diffusion out of the crystal when precipitates were removed from the 
surrounding solution.   
 After crosslinking crystals were rinsed by looping them and moving them 
sequentially through 3, 3 µL, drops of buffer.  Buffer conditions were 50 mM HEPES pH 
7.5 with 100 mM NaCl.  After washing, the crystals were transferred to a 3 uL drop of 
buffer containing 1-10 mM ligand for 1-10 minutes.  It proved important to check the pH 
of ligand solutions by dropping 0.5 µL onto pH paper.  In many cases pH had to be 
adjusted due to acidity of the ligand associated material overwhelming the buffer.  After 
soaking in the peptide solution, the crystals were briefly dunked in buffer containing 25% 
glycerol then cryogenically frozen in liquid nitrogen [93]. 
TOP activity control 
 As a control for residual TOP activity acting on bound peptide ligands, N-
truncated TOP crystals were subjected to ≥12 hour soaks in peptide soak buffer with 1 
mM EDTA.  This was followed by normal soaking in ligand solutions, which also had 1 
mM EDTA added.    
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Data collection and processing 
 Datasets were collected remotely at Argonne National Lab’s Advanced Photon 
Source (APS) SER-CAT beamlines 22 ID or 22 BM.  Data were reduced using the 
software suite HKL2000 [94].  Phases for dual-truncated TOP were found by molecular 
replacement with N-truncated TOP using the program Phaser [95, 96].  Subsequent 
rounds of refinement were carried out using PHENIX [97].  Ligand densities were 
initially modeled in COOT [98] using the Fo-Fc maps generated by PHENIX after one 
round of rigid body replacement with the structure of unliganded TOP.  Figures were 
made using Pymol (Delano Scientific). 
Isothermal titration calorimetry 
 Isothermal titration calorimetry was done using a VP-ITC (Microcal LLC.) 
instrument.  Protein concentration was adjusted such that 10 < 𝑐 < 100  where c =
 [thimet oligopeptidase]
expected association constant
  according to the recommendations of [99, 100] for 
experiments in which K, H, and S are determined.  An exception was made for 
neurotensin because it would have required more than 15 mg/ml concentration to satisfy 
this, and in this case c = ~7.   The concentration of peptide ligand was adjusted so that the 
final mole ratio of substrate to enzyme was in the range of 1.2 – 2.0.  Thimet 
oligopeptidase stock was concentrated by ultrafiltration immediately prior to ITC runs, 
with the concentration estimated from the absorbance at 280 nm (Nanodrop VD 1000 
spectrometer; Thermo Scientific).  Ligand concentration was also determined using the 
Nanodrop when ligands contained a tyrosine.  All extinction coefficients were calculated 
using the online ProtParam tool [101].  Ligand solutions for injection were diluted from 
~100 fold concentrated stocks with the flowthrough from protein concentration by 
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ultrafiltration.  Using the flowthrough from ultrafiltration minimized extraneous signal in 
the ITC resulting from any differences in buffer composition between the ligand and 
protein solutions. 
 Data analysis was carried out using Origin 7.0 software (Microcal).  Peaks were 
initially integrated then all curves were fit using the one site non-linear least squares 
regression function.  Control runs titrating ligand into buffer without enzyme were 
subtracted from the calculated heats of binding prior to curve fitting.  Even after 
subtracting heats of dilution most runs approached 0.1 - 0.5 kcal/mol in their final 
injections rather than zero, so a constant was subtracted from all injections such that the 
final 6-7 heats of injection approached zero. 
Identification of cleavage sites for angiotensin II and dynorphin B(1-9) 
 Angiotensin II (American Peptide Inc.) or dynorphin B(1-9) (Anaspec Inc.) were 
dissolved to a final concentration of 150 µM in reaction buffer of 50 mM HEPES pH 7.5, 
100 mM NaCl.  Purified N15_C2S_TOP also in reaction buffer at a final concentration of 
0.075 µM was incubated with angiotensin II or dynorphin B(1-9) at 37oC for one hour.  
At the end of incubation the reaction was stopped by adding formic acid to a final 
concentration of 0.25%.  Reaction mixtures were then subjected to HPLC analysis (C18 
column) and MALDI-TOF analysis at the University of Kentucky, Center for Structural 
Biology Protein Core Facility (Figure 3.4).    
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Nano test tubes 
Porous aluminum oxide template 
50 and 100 nm diameter pore size templates 
 To avoid the fragility of commercial templates manufactured using a standard 
two-step anodization method [102], anodic aluminum oxide template (AAO) was 
prepared in-house by treating Al film with a one-step anodization procedure.  The depth 
of the pores and thus the length of the nano test tubes produced using the template was 
controlled by the thickness of aluminum deposition prior to anodization.  Aluminum for 
50 nm pore size AAO was deposited to the desired depth (0.125, 0.25, 0.5 or 1 µM) on a 
silicon wafer about 2 cm2 using electron beam evaporation (Torr International, Inc. model 
EB-4P-6kW).  The silicon wafer with aluminum was subsequently anodized at 40 V in 
0.3 M oxalic acid at 20oC for 2 min.  Finally, the pores were allowed to widen in 5% 
phosphoric acid for 40 min.   
 100 nm AAO template was made in a similar fashion to 50 nm template.  Briefly, 
1 µm aluminum on a 6 cm2 silicon wafer was anodized at 120 V in 5% phosphoric acid at 
4oC, for 90 min.  Template pores were then widened by soaking templates for 40 min in 
5% phosphoric acid. 
200 nm pore size templates 
 Porous aluminum oxide with 200 nm pore diameters was also used as a template 
to make nano test tubes, but in this case commercially available AAO templates, or 
Anodiscs, (Whatman part #6809-6022) were used.  The Anodiscs were placed on a 1 mm 
thick glass support and mounted on a spin coater (Chemat Technology model KW-4A).  
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Then epoxy was mixed (Buehler Epoxicure heat curing epoxy) using 1 g epoxy, 0.2 g 
hardener, and 0.2 g acetone (to thin the mixture).  The epoxy was applied over the surface 
of the aluminum filter and allowed to soak in for 1 min before starting the spin coater.  
The samples were spun for 1 min at 3000 rpm to spin off excess epoxy.  Epoxy was 
allowed to cure overnight then excess epoxy was removed further using a Buehler Eco-
met polisher with 1 µM alumina polishing grit applied.  The aluminum filters were 
transparent after soaking up epoxy and reflective after final polishing.  The epoxy was 
then oxidatively etched to the desired depth of 0.25 - 1 µm using plasma generated in a 
Plasma Enhanced Chemical Vapor Deposition system (Tek Vac Industries model PE-
CVD 60-R).  The etch rate was approximately 250 nm/min. with settings Rf = 150 W, 
pressure = 0.7 Torr, air flow rate = 20.0.  Etching time was 1, 2, and 4 min. to produce 
250 nm, 500 nm and 1 µm pillars, respectively. 
Non-destructive replication 
  Replication was carried out following the manufacturer’s (Ted Pella) replicating 
tape protocol, briefly:  The surface of the AAO was wetted with acetone using a cotton 
swab (Figure 2.4).  Then replicating tape (0.22 µm thick, Ted Pella catalog #44840), a 
cellulose acetate film, was allowed to contact the wet surface with minimal pressure.  The 
acetone was allowed to dry for 30 sec after which time the sample was completely dry.  
Then the replicating tape was peeled off the hard template (Figure 2.5).  Cellulose acetate 
shrinks slightly upon solvent evaporation allowing easy release of the polymer from 
AAO template.  Templates could be recycled more than 100 times without any significant 
effect on nano test tube size or quality.  Polymer pillars with heights ranging from 125 
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nm - 1 µm were replicated successfully from AAO with pore diameters of 200 nm, 100 
nm, and 50 nm.  
Metal deposition 
 Once imprinted with a carpet of pillars complementary to the pores of the AAO 
template, nano test tubes were fabricated by sputter coating the replication tape with one 
or more thin layers of metal (silicon, aluminum, titanium, and/or gold).  Wetting of the 
polymer during replication caused the cellulose acetate replication tape to curl.  
Therefore, it was necessary to affix the tape corners to a solid support with double sided 
carbon tape during metal deposition (Figure 2.5). The pillars were spun at least 10 
rotations total during the deposition in order to insure an even coating.  Metal thickness 
was measured using quartz thickness monitors as it was deposited.  In cases of multiple 
metal layers each layer was 2.5 - 5.0 nm thick amounting to no more than 8 nm total.  
After metal coating, replication tapes were cut off the solid support taking care to ensure 
that no carbon tape was included in the excised samples. 
Test tube release and polymer removal 
 Metal coated nanopillars were released from the surface of the replicating tape by 
sonication in a standard bath sonicator (Sonicor model SC-50TH) for 15 min.  Successful 
pillar breakage could be visually assessed in gold coated samples as areas of slightly 
lighter blue tinted replicating tape after sonication.  Also, gold coated nano test tubes 
could be seen as a blue coloring in suspension (Figure 2.6).  In order to estimate test tube 
yield absorbances of test tubes per mg of gold were compared to that of standard gold 
colloid.  100 µL of suspensions made by sonicating 36 cm2 replicated pillars in 5 ml of 
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water were added to a 96-well plate.  Absorbances were measured in a microplate reader 
(Bio Tek) and adjusted for a path length of 0.29 cm [103].  Absorbances were compared 
using the peak wavelength of 530 nm for colloidal gold and 650 nm for nano test tubes. 
The expected mg of gold in the nano test tube sample was calculated assuming a typical 
76% yield and tubes with the measured deposited gold thickness (3 nm) on the tips, but 
only 1 nm gold on their side walls.   
 In order to track the settling of nano test tubes a similar 36 cm2 sample of 100 nm 
x 1 µm tubes was used.  Settling was followed by adding 2 ml of suspension to a 1 cm 
plastic cuvette and monitoring the OD600 over time in a spectrophotometer (Eppendorf 
Biophotometer).  The cuvette was capped with parafilm and left undisturbed for the 
duration of the experiment. 
Test tube particle characterization 
 Electron microscopy was carried out at the University of Kentucky College of 
Engineering’s Electron Microscopy Center.  For scanning electron microscopy (SEM) 
nano tubes suspended in water were collected by filtering the samples through 20 nm or 
200 nm pore size Whatman Anodisc filters.  Then the filters were broken into portions 
and secured on aluminum SEM specimen mounts (Ted Pella #16221) using colloidal 
graphite (Ted Pella # 16053).  Replicating tape and AAO template samples were also cut 
or broken and mounted for SEM imaging using colloidal graphite.  All SEM samples 
were sputter coated with ~15 nm of gold/palladium for conductivity during SEM 
imaging.  Micrographs were taken in a Hitachi S_4300 scanning electron microscope 
using the following settings: accelerating voltage = 3.0 kV, aperture = #4, working 
distance = 15.0 mm, condenser lens setting = 8.0.   
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 In order to check if nano test tubes broke off the replicating tape cleanly or carried 
a polymer core with them, 200 nm diameter tubes were filtered and exposed to oxidative 
plasma etching in a plasma cleaner (Harrick) for 40 minutes.  Plasma generation settings 
were Rf = High, O2 flow rate = .8 sccm. 
 For transmission electron microscopy (TEM) nano test tubes were mounted on 
LaceyTM carbon grids (Ted Pella #01881).  The nano test tubes were mounted by placing 
the grid onto parafilm and pipetting 5 µL of water onto the TEM grid.  Replication tape 
with metal coated pillars was gently rubbed against the TEM grid / parafilm in this small 
volume of water.  The physical turbulence in a small volume of water acted as a 
substitute for sonication to release a suitable number of test tubes for TEM imaging.  
Transmission electron micrographs were obtained using a JEOL 2010 FX microscope 
operated at 100 kV. 
Nano test tube biotinylation 
 Multiple approaches were taken in an effort to remove the polymer core from 
nano test tubes.  36 cm2 of 100 nm x 1 µm imprinted pillars were prepared (~100 cm2 
total surface area) and coated with their respective metal(s) then subjected to 1 hr of 
oxidative plasma etching.  The etched tapes were then immersed in water and sonicated 
for 15 min to break apart tubes.  Nano test tubes were filtered from water using a 13 mm 
diameter Whatman anodisc filter with pore size of 20 nm.  Then the tubes / filter were 
washed three times with acetone and dimethylformamide.  The tubes / filter were burned 
in air in a furnace at 500oC for one hour.  Finally, they were washed again with acetone 
and dimethylformamide.   
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 These “hollowed” tubes were equilibrated for functionalization by rinsing with 
DMSO, then resuspended by sonication in DMSO with 1 mM biotin-PEG-SH added 
(monothiolalkane(C11)PEG6-biotin, Sensopath Technologies Inc. part number SPT-
0011P6-BIOTIN, MW = 694) (Figure 2.7).  After 3 hrs in 1 mM biotin-PEG-SH at room 
temperature the particles were collected onto a new filter and washed: washes consisted 
of six 0.5 ml washes of DMSO followed by six 0.5 ml washes with isopropyl alcohol 
followed by three 0.5 ml washes with water.  After washing, the filter was broken and the 
pieces were immersed in a microfuge tube with 150 µL of a biotin detection kit (Quant 
Tag, Vector Labs, Inc. part number BDK2000) working solution.  150 µL of Quant Tag 
working solution was simultaneously added to biotin standard solutions.  Metal oxides 
catalyze the same color change in the Quant Tag working solution as does biotin, 
however, biotin changes color in minutes while oxides require >30 min, allowing a short 
window of time to assess the biotin labeling.  Samples were sonicated for 5 min in 
working solution then centrifuged for 30 sec at 13,000 rpm to pellet particles.  100 µL of 
each standard and sample were transferred to a 96-well plate and absorbances for all 
wavelengths from 500 nm - 650 nm (535 nm is the wavelength of interest, but assessing 
spectrums around that value assure that no particles are interfering) were collected 
immediately using a microplate reader (Bio Tek).  Biotin was quantified by comparing 
the absorbance of samples at 535 nm to a standard curve.    
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sense           5'-ggggctgcaggtctagggctgcgagccc-3' 
antisense       5'-gggctcgcagccctagacctgcagcccc-3' 
 
 
 
MADIGS then: 
16  SSPCSVVNDLRWDLSAQQIEERTRELIEQTKRVYDQVGTQEFEDVSYESTLKALADVEVTY 75 
76  TVQRNILDFPQHVSPSKDIRTASTEADKKLSEFDVEMSMREDVYQRIVWLQEKVQKDSLR 135 
136 PEAARYLERLIKLGRRNGLHLPRETQENIKRIKKKLSLLCIDFNKNLNEDTTFLPFTLQE 195 
196 LGGLPEDFLNSLEKMEDGKLKVTLKYPHYFPLLKKCHVPETRRKVEEAFNSRCKEENSAI 255 
256 LKELVTLRAQKSRLLGFHTHADYVLEMNMAKTSQTVATFLDELAQKLKPLGEQERAVILE 315 
316 LKRAECERRGLPFDGRIRAWDMRYYMNQVEETRYCVDQNLLKEYFPVQVVTHGLLGIYQE 375 
376 LLGLAFHHEEGASAWHEDVRLYTARDAASGEVVGKFYLDLYPREGKYGHAASFGLQPGCL 435 
436 RQDGSRQIAIAAMVANFTKPTADAPSLLQHDEVETYFHAFGHVMHQLCSQAEFAMFSGTH 495 
496 VERDFVEAPSQMLENWVWEQEPLLRMSRHYRTGSAVPRELLEKLIESRQANTGLFNLRQI 555 
556 VLAKVDQALHTQTDADPAEEYARLCQEILGVPATPGTNMPATFGHLAGGYDAQYYGYLWS 615 
616 EVYSMDMFHTRFKQEGVLNSKVGMDYRSCILRPGGSEDASAMLRRFLGRDPKQDAFLLSK 675 
676 GLQV 679 
 
Figure 2.2  Amino acid sequence of purified dual truncated TOP.  The above TOP 
sequence was deduced by trypsin digest followed by MS/MS.  The observed total mass 
was 76,906 kDa, and C-terminal fragment weights agreed with a truncation after Val 
679.  Fragmentation of the N-terminal fragment revealed an extra 645 Da corresponding 
to a cloning artifact from the pET32a vector (MADIGS sequence). Mutations other than 
truncation are highlighted.  Numbering scheme is based on the native sequence. 
 
Figure 2.1  Dual truncated TOP primers. The above DNA sequences were used to 
replace Gly680 of N truncated TOP constructs with a stop codon. 
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Figure 2.3  Crystallized TOP.  a) N-truncated TOP crystals b) Dual truncated TOP 
crystals.  
33 
 
 
   
 
 
Figure 2.4  Schematic of non-destructive replication method.  Therapeutic quantities 
of nano test tubes were synthesized in four stages a) Porous alumina formed on a silicon 
wafer is used to imprint softened polymer multiple times. b) Pillared replicas are coated 
with desired metal(s). c) Nano test tubes are freed by sonication in aqueous solution and 
finally suspended particles are collected d).   
 
a)  
 
b)  
 
d)  
 
c)  
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Figure 2.5  Non-destructive template replication. a) Imprinting replicating tape from a 
porous template.  b) Preparation for coating.  Double sided carbon tape was used to hold 
replicated pillars flat against a microscope slide during metal deposition.   
 
(a)  
 
(b)  
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Figure 2.6  Suspended nano test tubes  a) gold/titanium hybrid test tubes (50 nm x 1 
µm dimensions) at a concentration of ~7 cm2 pillared replicas per milliliter b) pure 
titanium test tubes of the same size and concentration. 
 
 
(b) 
 
 
(a)  
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Figure 2.7  Resuspension of nano test tubes after filtration a) 20nm AAO filter used 
for filtering titanium coated gold nano test tubes.  Tubes were resuspended from filter by 
sonication. b) A film of tubes remains on filter after parallel experiment using solid gold 
nano test tubes. 
 
 
(b)  
 
 
(a)  
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CHAPTER THREE: Thimet oligopeptidase substrate recognition 
 Our goal was to understand the molecular mechanism behind the broad substrate 
recognition of neuropeptidases by mapping the binding surface and determining the 
number and types of interactions found at the peptidase - peptide interface.  We chose 
TOP as a model neuropeptidase and determined its structure in complex with a variety of 
substrates by crystal soaking experiments followed by X-ray structure determination.  
These structures show the extent of the interface that mediates initial substrate 
interactions and define a new class of peptide binding surface unique to neuropeptidases.   
 This study is a continuation of work begun previously in the lab by Nick Noinaj.  
Nick was the first to discover that soaking TOP crystals in dilute substrate solutions 
allowed substrate complex formation.  His subsequent structures allowed modeling of 
angiotensin II and dynorphin A(1-13) TOP complexes and identified the TOP binding 
site on domain II across from the active site.  These structures explained, in part, TOP’s 
broad sequence recognition and preference for hydrolyzing near the C-termini of 
substrates.  However, angiotensin II and dynorphin A(1-13) are not efficiently 
hydrolyzed by TOP, and Nick’s models of efficiently hydrolyzed substrates suffered from 
poor occupancy preventing accurate model building.  Consequently, he concluded that 
residual hydrolytic activity was preventing determination of complete TOP / substrate 
complexes [104].  My structures add eight full-length substrate complexes to the first two 
including seven substrates that are not considered resistant to TOP hydrolysis.  In 
addition, my improved substrate models and controls for TOP activity clearly indicate 
that all ten complexes are likely to contain the full-length substrate.  Finally, the 
recapitulation of complex structures using a truncated version of TOP allowed 
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identification of a previously obscured substrate - induced rearrangement of the binding 
surface.  
TOP constructs used in structural studies 
 For some of the  TOP-peptide crystal structures determined, a TOP construct 
(residues 16-689)  previously reported [49], was used.  The C-terminus of this construct 
is disordered beginning at Leu677 [49].  In the course of the structural studies reported 
here, additional C-terminal residues appeared in some structures collected from crystals 
that had formed more than two weeks before being harvested.  These structures showed 
an intermolecular disulfide bond formed between Cys175 and Cys682, and in some cases, 
I was able to model the remainder of the C-terminal residues.  In those cases, the ordered 
C-terminus reached all the way to the active site zinc ion where the C-terminal 
carboxylate was seen to participate in coordination of the metal ion (Figure 3.1).  
Modeling suggested that it was even possible that the C-terminus may interact with the 
substrate binding site identified in this work, raising concerns about artifacts (Figure 3.2).   
 To prevent interference with substrate binding in the crystals we designed a 
truncated construct by changing Gly680 into a stop codon (see Chapter 2).  To determine 
if removing the C-terminus of TOP affected TOP function, we subjected inactive, 
truncated, TOP to isothermal titration calorimetry (ITC) and found that binding isotherms 
were identical to untruncated enzyme for representative substrates (see Chapter 4).  
Similarly, activity assays using quenched fluorescent neurotensin (Abz-NT-edd) showed 
comparable activity for dual truncated TOP (Figure 3.3).  This indicates that removing 
the C-terminal residues does not significantly alter TOP function. 
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 Dual truncated TOP required new conditions for crystal growth.  Final 
crystallization conditions (100 mM CHES pH 8.3, 400 mM MgCl2, 12-15% PEG 6000) 
yielded crystals with high resolution diffraction and very similar unit cell parameters as 
N-truncated TOP (Table 3.1). Phases were found using the N-truncated TOP structure 
(PDB code 1S4B) for molecular replacement with Phaser [95, 96].  The resulting maps 
revealed a structure very similar to N-truncated TOP and refined models were 
superimposible with a rmsd of 0.57Å.   
Choice of substrates for structural study 
 TOP cleaves a large number of bioactive peptides in vitro, and alignment of 
known cleavage sites reveals no distinguishing features that specify a preferred amino 
acid sequence.  In order to understand how TOP recognizes so many different sequences, 
substrates were chosen for structural studies to contain as wide a variety of lengths and 
sequences as possible.  Tables 3.2-3.4 summarize substrates and inhibitors used in 
attempts to determine crystal structures based on the literature reports of cleavage by 
TOP [16, 24, 25, 105-111].  Only a relatively small number of trials yielded interpretable 
electron density for ligands (see Tables 3.5, 3.6), and the set of TOP-ligand structures 
reported here is biased toward enkephalin-like sequences 8-13 residues in length.  
 For two of the peptides that yielded good complex structures, angiotensin II and 
dynorphin B(1-9), cleavage by TOP has not been well characterized.  Our mass 
spectrometry analyses of digestion products indicated that angiotensin II is cleaved at 
Arg2-Val3 (Figure 3.4).  In addition, the hydrolysis rate (<5% that of adrenorphin) was 
found to be particularly slow in one study [110].  Dynorphin B(1-9) is a leu-enkephalin 
containing opioid peptide fragment reputedly produced in vivo by degradation of 
40 
 
dynorphin B(1-13) [112, 113].  It has never been reported as a TOP substrate in the 
literature. 
Overview of complex structures 
 In our structures TOP always adopts a fold shaped much like an open clam shell 
with two large domains divided by a deep cleft.  A narrow hinge connects the two 
domains at the bottom and allows for a large hinge-closing motion like that seen in 
related enzymes [51, 114].  Domain II coordinates the active site zinc ion located near the 
bottom of the cleft equidistant from either cleft end.  Across the cleft from the active site 
is a mobile loop predicted to be involved in substrate binding and recognition [115, 116].  
Analysis of related peptidase/inhibitor complexes shows that after closure substrates 
typically orient themselves just above the active site and antiparallel to the innermost 
strand of the beta sheet located on domain II [51, 52].  Because substrates bridge the 
interdomain cleft and form interactions with both domains in these closed structures a 
major goal of this work was to discover which domain(s) interact with substrates in the 
open conformation during initial substrate recognition.   
A major finding of this work is that bound peptides most frequently interact with 
a surface on the side of the central channel (domain I) opposite the active site rather than 
directly at the active site as expected.  Out of the total of 18 refined crystal structures, ten 
yielded identifiable ligand density at the domain I substrate-binding site (Figure 3.5).  In 
the case of efficiently processed TOP substrates (adrenorphin, dynorphin A(1-8), 
dynorphin B(1-9), bradykinin, and neurotensin) only partial density was observed 
corresponding to the C-termini plus 3-6 residues interacting solely with domain I.  This is 
an indication that initial binding determinants are concentrated near the C-termini of 
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peptide substrates, and a single domain - domain I - is initially responsible for binding 
substrates.  These structures generally became disordered between the P1’ and P2 
residues where the peptide backbone juts out across the interdomain cleft.  
For example, neurotensin (1-13) binds to domain I through residues 7-13 with 
sequence PRRPYIL.  Like all substrates, the neurotensin residues closest to the N-
terminus become gradually more disordered so the full shape of proline 7 cannot be 
distinguished.  Therefore, our model includes the sequence ARRPYIL, substituting an 
alanine for proline 7 (Figure 3.5).  The substrate-binding surface is made up of primarily 
helical elements from domain I.  Helices 19 and 21, along with ten loop residues just 
prior to helix 21, contribute most of the binding surface.  Helices 7 and 12 contribute 
several residues that interact with the C-termini of substrates.  Helices 7 and 8 partially 
close off one end of the surface. The surface is relatively flat, and it is rich in aromatic 
and hydrophobic residues, making it carbon rich relative to the rest of the enzyme 
surface.  Specifically, the side chains of aromatic residues Tyr221, Phe225, Phe550, 
Phe598, Tyr605, Tyr609, Tyr612, and hydrophobic residues Leu557, Met594, and 
Leu613 contribute to the surface.  Charged and uncharged polar side chains also 
contribute including Arg338, Arg553, Gln554, His600, and Glu616.  The total surface 
area interacting with substrates varies between 400-600A2. 
Recognition based on C-terminal residues 
 The majority of TOP/substrate complexes reveal only partial electron density for 
ligands (Figure 3.6-3.10), with residues C-terminal to the scissile bond primarily visible. 
Generally, density for residues N-terminal to the cleavage site is limited to one or a small 
number of residues, and side chain density is usually not present.  More specifically, 
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residues located at positions 4-6 from the C-terminus, corresponding to P2-P1’ positions 
relative to the cleaved bonds are typically less ordered and were modeled as mainchain 
only.  His600, and Tyr612, provide hydrogen bonds to the mainchain carbonyls of those 
residues 4th and 5th from the C-termini while Tyr605 hydrogen bonds to the amide of the 
6th residue suggesting it plays the same role as Tyr486 of PZ Peptidase A [117] and 
Tyr607 of DCP [51].   The 7th residue from the C-termini invariably becomes too 
disordered to model in the narrowest part of the cleft between Tyr605 and the active site. 
It is possible that the reduced  N-terminal residue electron density is due to 
hydrolysis or partial hydrolysis by the residual activity of the enzyme [104].  An 
alternative explanation is that the N-termini of the substrates are disordered and so do not 
result in detectable electron density as they extend out of the identified binding site.  In 
order to resolve these two possibilities, the active site Zn ion was removed by introducing 
EDTA prior to substrate soaks in order to completely inactivate the enzyme.  The 
resulting complex structures clearly had the Zn removed, but little or no additional 
density was seen extending out of the domain I binding site (Figure 3.11).  (Interestingly, 
one of the substrates that never yielded identifiable density - LHRH - was found to 
accelerate removal of the active site Zn by EDTA (Figure 3.12).  It might be helpful in 
the future to include LHRH in EDTA soaks of sensitive crystals in order to lower the 
soak time.)  The only change to ligand density due to Zn ion removal occurred in the case 
of adrenorphin where a second adrenorphin molecule was found to bind to domain II 
(Figure 3.13) in the EDTA treated crystals, but density for adrenorphin bound to the 
original binding site on domain I remains unchanged.  Since these carefully inactivated 
enzyme structures show exactly the same ordered and disordered residues as their Zn 
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containing counterparts it is likely the residues N-terminal to the scissile bond in our TOP 
complex structure are not well ordered. 
 The well ordered state of substrate C-terminal residues is consistent with studies 
showing that TOP recognizes dynorphin A(1-13), neurotensin, and bradykinin via 
interactions with C-terminal residues and subsequently can become inhibited by C-
terminal product fragments [44, 104].  It is also consistent with studies showing that 
seemingly minor sequence changes near the C-terminus can result in cleavage site shifts 
[110].  The disordered state of substrate residues adjacent to the cleaved bonds and near 
the N-terminal suggests that these residues are not involved in initial substrate binding.  
Each structure showed C-terminal residues interacting with the main binding site on 
domain I indicating that the TOP binding site selects for C-termini.  Thus, a consistent 
picture emerges where TOP initially recognizes substrates based on residues C-terminal 
to the cleaved bond, and the orientation of the peptides inside the channel is strictly 
enforced. 
Binding determinants overview 
Aspects of the substrate-binding surface and the observed peptide binding 
interactions suggest a basis for the broad substrate recognition shown in TOP.  The 
binding interactions are summarized in Table 3.7.  There are few polar interactions to 
side chains that would provide specificity for amino acid type.  Instead side chains deploy 
in shallow grooves that typically can accommodate multiple amino acid classes (Figure 
3.14a, Figure 3.15).  In contrast, there are often a substantial number of hydrogen bonds 
to the main chain of the bound peptide, enhancing affinity in a manner largely 
independent of sequence.  These hydrogen bonds are not strongly directional, and the 
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relatively flat binding surface, rich in carbon, allows the peptides to adjust their path to 
optimize contact and accommodate sequence dependent variations in backbone 
conformation and side chain placement (Figure 3.14a).  Shifts in main chain path across 
different bound peptides of up to 1 Å occur.  In all cases, over 50% of the accessible 
surface area of the peptide segment is buried in the binding interaction.  
Surprisingly, the registration of the scissile bond varies in our structures.  In 
particular, the scissile bond varies by plus or minus one subsite position relative to 
features of the binding surface (Figure 3.14b), and this registration variability may have 
implications for the mechanism of substrate binding and cleavage.  Given these shifts in 
registration, we will not use the normal subsite nomenclature for peptidases [118] but 
simply refer to subsites 1-3, with subsite 1 being closest to directly opposite the active 
site (Figure 3.16).   
Small conformational shifts can be observed when the binding sites of the 
different peptide complexes are aligned.  There are some variations at the C-termini of 
substrates caused by small concerted movements in the bottom half of domain I (Figure 
3.17a,b).  These movements are analogous to the differences seen in this domain between 
the structures of TOP and neurolysin [49], and also between neurolysin and the 
neurolysin N25 construct [119].  In our structures these shifts never pushed the C-
terminus of peptides far enough to result in a new registration, which would be a potential 
mechanism for final alignment of the scissile bond with the active site that would account 
for the observed differences in peptide registration.  It is tempting, however, to speculate 
that larger shifts might occur in solution.  There are also small changes of side chain 
conformations in residues of the binding surface as it reorganizes in response to ligand 
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binding, and these also likely contribute to broad substrate sequence recognition (Figure 
3.17c). 
Subsite 1 
 This site (Figure 3.18) interacts with the 3rd or 4th residue from the C terminus in 
the structures determined.  It consists of a shallow groove formed primarily by the 
aromatic rings of Tyr612 and Phe550 on either side, and the side chain of Glu616 is 
located at the end of the groove.  This subsite is an excellent example of one capable of 
accommodating different residue types, and the structures determined show leucine, 
proline, arginine, and lysine residues binding here.  The rings of Tyr612 and Phe550 can 
interact with hydrophobic (or potentially aromatic) side chains and the aliphatic portion 
of long charged side chains.  When arginine or lysine interact at this position they form 
an additional salt bridge to Glu616 (Figure 3.18).  The presence of Glu616 confers some 
specificity at this site, since it would prevent negatively charged residues from 
interaction, at least in the same extended conformation as that observed for the bound 
arginine and lysine side chains.   
Subsite 2 
 Subsite 2 generally interacts with the 2nd or 3rd residue from substrates’ C-termini. 
Side chains from several hydrophobic/aromatic residues, Leu557, Met594, and Phe598, 
form most of the subsite surface, although polar or charged side chain and main chain 
groups from Tyr221, Arg553, Thr597, His600, and Tyr609 also contribute.  Unlike 
subsite 1, subsite 2 has polar residues perfectly oriented to donate two hydrogen bonds to 
the backbone of substrates.  Tyr609 accepts a bond from the backbone amide of the 
ligand residue occupying the subsite in all complex structure, and Arg553 and Gln554 are 
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both oriented to donate hydrogen bonds to the main chain carbonyl oxygen.  In the 
absence of ligand Gln554 may rotate to donate a hydrogen bond to Tyr609.  Residues 
occupying subsite 2 in the complex structures are highly variable in type, including 
arginine, histidine, glutamine, leucine, tyrosine, and phenylalanine (Figure 3.19). Again, 
this subsite is a good example of a portion of the binding site surface that has evolved in 
such a way as to accommodate a variety of residue types.   
Subsite 3  
 Subsite 3 (Figure 3.20) interacts with the C-terminus of peptides bound in the 
standard manner at the substrate binding site, and binding interactions at this subsite are 
the most variable that were observed.  Arg338 and Arg553 make up a prominent portion 
of subsite 3, but there is also an extensive cluster of aromatic and hydrophobic residues, 
including Phe550, Met337, Met341, Leu549, Leu584, Tyr220, Tyr221, and F225 that 
makes up the distal portion of the surface.  Many of the side chains making up this 
subsite adjust their conformations to accommodate different peptide substrates.  Arg338, 
Arg553, Tyr221, and Phe225, in particular, have multiple conformations in the 
unliganded TOP structure and adapt to the presence of substrates.  Residues occupying 
this subsite are again highly variable in nature with hydrophobic, aromatic, and charged 
side chains represented in the crystal structures. The side chains deploy in different 
orientations and in some cases are not well ordered.  The C-terminal carboxylate most 
frequently interacts with Arg338, but it also sometimes interacts with both Arg338 and 
Arg553 – in one case exclusively with Arg553.  The side chains of the two arginines 
from the enzyme adjust conformation to track the variable positions of the carboxylate 
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oxygens, forming a moldable recognition site for the C-terminus of the peptide (Figure 
3.21).  
Interestingly, the aromatic residues Tyr221 and Phe225 (from TOP helix 7 and 
the region N-terminal to it) is a highly conserved motif in TOP orthologs (Figure 3.22) 
confirming the observation here that it plays an important role in substrate binding.  
Along with Tyr224 this aromatic cluster largely makes up the surface that partially closes 
off one end of the substrate binding site (Figure 3.20).  Any substrate binding in such a 
way as to extend beyond this defined end of the site would have to adopt a sharp turn in 
main chain path in order to avoid this cluster of side chains.  The positions of Tyr221 and 
Phe225 are variable in unliganded TOP, and they can be crowded into a variety of 
positions by the C-terminal residue of substrates (Figure 3.17c).   
 Taken together, these three subsites clearly allow binding of many diverse 
sequences.  How then is any specificity toward the recognized cleavage site sequences 
achieved?  One easy example would be the exclusion of negatively charged residues from 
subsite 1 due to the presence of Glu616.  In addition, amino acids such as glycine, 
alanine, and serine with short and/or polar side chains would leave subsites unfilled or 
interact in an energetically unfavorable manner with hydrophobic portions of the subsites.  
Interestingly, affinity for amino acids with larger side chains is shared in peptide 
recognition by the major histocompatability complex proteins of the immune system, 
which use aliphatic or charged residues at or near the C-terminus of peptides to anchor 
binding [120].   
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Differences in the dual truncated form of TOP: the 599-611 residue 
region 
 As noted, concern over possible interaction with the C-terminus of an adjacent 
TOP molecule prompted use of a TOP construct in which the unstructured C-terminal 
residues had been removed. The only significant differences between the backbones of 
dual truncated and N truncated TOP near the substrate-binding and active sites were 
found in the open coil region N-terminal to helix 21 (residues 599-611).  In dual 
truncated TOP Tyr605 points across the interdomain cleft towards Asp83 and His600 
points towards the interior of TOP where it forms a hydrogen bond to the mainchain 
carbonyl of Tyr605.  In N truncated TOP described by Ray et. al. [49] Tyr605 swings 
5.2Ao towards the active site carrying the backbone of residues 603-605 up to 1.8Ao 
towards His600.  His600 adopts a new rotamer and faces solvent instead of hydrogen 
bonding to the backbone carbonyl of Tyr605.  Also, in N truncated TOP Arg498 adopts a 
more extended side chain rotamer, but in dual truncated TOP Tyr605 forces Arg498 into 
a less extended conformation.   
Subsequent structures of dual truncated TOP with substrates induced 
conformational changes resulting in a return to the conformation of the 599-611 region 
seen in structures determined from crystals containing the full C-terminus of TOP.  A 
possible explanation for the observed structural difference is that interaction of the C-
terminus of a neighboring TOP molecule with the active site region (see Figure 3.23) 
displaces the conformation of the 599-611 region.  In particular, it might shift Gly603-
Tyr605 in the 599-611 loop into the liganded conformation.  An alternative explanation is 
that the C-terminus of an adjacent molecule interacts in a disordered way with the 
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substrate-binding site, altering the conformation of the 599-611 region in the same 
manner as a bound substrate peptide.  The C-terminal residues would have to be 
sufficiently disordered so as to not give rise to substantial electron density in the crystal 
structures, since none is observed. 
The rearrangements of the 599-611 region are stabilized by hydrogen bonds that 
form to substrates consistent with mutational studies replacing glycines with alanines 
and/or tyrosines with phenylalanines [115].  The increased backbone flexibility provided 
by conserved glycines 599, 603, and 604 is key in permitting rearrangement of the 599-
611 loop.  Substrate binding causes a moderate displacement of Gly603 and Gly604 
along with Tyr605, allowing Tyr605 to hydrogen bond to the substrate backbone.  Aided 
by the flexibility of Gly599, His600 shifts and adopts a new rotamer allowing it to 
hydrogen bond to substrate backbone as well (Figure 3.23a).  Interestingly, Gly611 and 
Tyr612 do not undergo a significant movement upon substrate binding, but Tyr612 still 
forms a hydrogen bond to the backbone of most of the substrates.   
It does not appear that mobility in the 599-611 region plays a role in 
accommodating different substrate sequences when they bind in the standard manner to 
the substrate-binding surface.  The conformations of this region are bimodal, with only 
the unliganded and liganded conformations observed.  No significant conformational 
differences are observed when all of the dual truncated TOP ligand-bound structures are 
superimposed (Figure 3.23b).  This suggests that the mobility of conserved glycines in 
this region does not support broad recognition but perhaps to some extent provides for an 
entropic cost that allows for specificity without excessively high affinity, as has been 
suggested for unstructured regions [121]. 
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Individual substrate analysis and exceptions 
Angiotensin II 
 Angiotensin II is an eight residue (DRVYIHPF) vasoconstricting peptide that 
plays a role in blood pressure regulation, and a structural relative of TOP known as 
angiotensin converting enzyme (ACE), produces this peptide from a larger precursor. 
TOP has also been identified as a protein that binds tightly to angiotensin II in the 
cytoplasm [122, 123].  Also, an enzyme closely related to TOP, neurolysin, has recently 
been identified as a tight binding membrane receptor for angiotensin II [124]. The 
structural determinants of angiotensin II binding to TOP are of interest for predicting the 
binding site on all family members including neurolysin and ACE, which is of 
considerable interest in understanding the physiological roles of the peptide.  
 I was able to determine a high quality structure of angiotensin II bound to TOP.  
Interestingly, this peptide extends out of the substrate-binding site to cross the 
interdomain channel of TOP and interact at the active site (Figure 3.24).  The first four 
residues form a short alpha helical structure and the N-terminal Asp1 coordinates the 
active site Zn ion.  The last four residues interact with the substrate-binding site in a 
conformation similar to other bound substrate peptides.  Ile5 from the peptide extends 
into hydrophobic subsite 1.  His6 extends into hydrophobic subsite 2.  Pro7 and Phe8 
displace Phe550 and the phenyl ring of Phe8 reaches deep into subsite 3 beyond the C-
terminal recognition motif (Figure 3.24c).  The orientation of angiotensin II brings the 
alpha carbonyl of Tyr4 into position for hydrogen bonding with His600.  Consequently, 
His600 partitions into its “liganded” rotamer.  Interestingly, Tyr605 does not follow 
His600 into the “liganded” conformation (Figure 3.24g).  This could be due to the 
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orientation of angiotensin II which carries the backbone out of range to hydrogen bond to 
the “liganded” conformation of Tyr605, or it could be due to interference from the 
(disordered) side chain of Tyr4.  In any case, it is notable that His600 can move 
independently of Tyr605 since in all other structures these two residues make a 
coordinated switch to the liganded form.  Also of note, in the N truncated TOP - 
angiotensin II complex Tyr605 does assume the liganded conformation, providing 
evidence that angiotensin II and the disordered C-terminal tail of a neighboring TOP 
molecule are simultaneously present in the vicinity of Tyr605. 
 Angiotensin II interacts mostly with the domain I binding site.  However, it forms 
two powerful interactions to domain II.  First, as noted, the carboxylic acid of Asp1 
participate in coordination of the active site Zn.  Second, Arg2 forms ionic interactions 
with Glu469 and Glu509 (Figure 3.24f).  Anchored in this way to the active site, 
angiotensin II cannot be placed into position for hydrolysis of a peptide bond by the 
hinge like conformational change of the enzyme. The structure, therefore, explains the 
extremely slow hydrolysis of angiotensin II (<5% hydrolysis rate as compared to 
adrenorphin [110]) and it is likely that rearrangement to another, less favorable binding 
interaction is required for hydrolysis by TOP. 
Immunoglobulin G4  
 Immunoglobulin G4 (IgG4) residues 279-287 (DSDGSFFLY) have been reported 
as a tight binding TOP ligand that is resistant to hydrolysis [16].  We determined the 
structure of IgG4 complexed to TOP to 2.5Å (Figure 3.25). The electron density is strong 
for the ligand, suggesting that IgG4 binds with high occupancy to the open conformation 
of TOP consistent with the reported Ki of 0.3µM.  The peptide binds to the same domain 
52 
 
I binding site as other substrates, but it adopts a different orientation, pointing across the 
interdomain cleft directly at the active site.  Also, unlike most substrates, this sequence 
has no interaction between the C-terminal carboxyl and Arg338.  Instead the peptide C-
terminus interacts with Arg553 and the terminal tyrosine side chain extends into subsite 
2. 
 Perhaps the most striking feature of the TOP - IgG4 complex structure is that it 
binds to the “unliganded” conformation of the 599-611 loop.  The orientation of IgG4 
does not induce the conformational changes in His600 or Tyr605 that normally 
accompany peptide interaction with the binding site.  As a consequence of its unusual 
interaction with the binding site, IgG4 has relatively few hydrogen bonds formed to its 
main chain for those residues interacting with domain I.  The bound peptide also interacts 
extensively with domain II, however.  The first four residues form backbone interactions 
with TOP’s beta sheet and the carboxyl group of Gly4 displaces the catalytic water at the 
active site to coordinate the active site Zn ion (Figure 3.25).  The observed registration of 
IgG4 would place the backbone of Phe7 in position to hydrogen bond with His600 and 
Phe6 to hydrogen bond with Tyr605 if it followed the typical path of substrates.  
However, IgG4 is similar to angiotensin II in that it spans the cleft directly towards the 
active site Zn.  This means Phe6 is too far from Tyr605 to interact with the liganded 
conformation of the 599-611 region.  The backbone carbonyl of Phe7 is actually in the 
correct place to interact with His600, however, the sidechain of Tyr8 appears to sterically 
restrict His600 from adopting its normal bound - ligand conformation.  Like angiotensin 
II, the orientation of IgG4 and its coordination of the active site Zn ion prevent it from 
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being aligned for hydrolysis.  In this case also, then, the bound structure is consistent and 
provides an explanation for the lack of or low activity of TOP with this peptide. 
Adrenorphin  
 Adrenorphin is a C-teminal amidated peptide cleaved three residues from the C-
terminus by TOP.  The structure of TOP with bound adrenorphin is unique in that two 
adrenorphin molecules bind in the central channel of the enzyme, one in the expected 
binding site in a fashion very similar to dynorphin A(1-8) and the other on domain II 
lying across the active site.  In interacting with domain II, adrenorphin does not bind in a 
registration relative to the active site consistent with the known cleavage site (Figure 
3.13).  Also, adrenorphin only achieves high occupancy at the domain II site in the 
absence of the active site Zn ion.  Structures of TOP complexed to adrenorphin without 
co-incubation with EDTA do not have adrenorphin bound to domain II.  Furthermore, 
cleavage assays of adrenorphin with catalytically compromised, E474A TOP, showed 
only the predicted YGGFM - RRV cleavage site.  Together these indicate that the 
presence of Zn ion prevents domain II binding, probably by blocking Val8 of the peptide 
from interacting with the pocket formed by Ala474 and Thr470.     
 The productive mode of adrenorphin binding, therefore, is most likely through 
initial interaction with the domain I binding site as seen in the dual truncated TOP 
complex with Zn present (Figure 3.19a, b).  Adrenorphin binding to domain I is very 
similar to other substrates so it seems that its binding to domain II, although instructive, 
is merely an artifact of the TOP construct used and the soak conditions which removed 
the active site Zn ion.  
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Luteinizing hormone releasing hormone and dynorphin B. 
 During the course of this work hundreds of TOP crystals have been grown and 
subjected to various ligand-containing solutions.  Most ligand solutions had only minor 
effects similar to what might be expected from small changes to the enzyme structure.  
However, there were at least two exceptions worth noting.  First, N truncated and dual 
truncated TOP crystals soaked with luteinizing hormone releasing hormone (LHRH, 
sequence EHWSYGLRPG) in the presence of EDTA lost their active site Zn ion in less 
than 30 minutes of soak time (Figure 3.12).  This is particularly surprising since this 
peptides was not seen binding in the structures determined from soaked crystals. 
Interestingly, LHRH was reported as not being a substrate for TOP [111].  LHRH must in 
some way interact at the active site to affect Zn ion binding, however, it clearly does not 
have a high affinity interaction with the enzyme. 
 Another peptide of particular interest is dynorphin B.  Both dynorphin(1-9) 
(YGGFLRRQF) and dynorphin B(1-13) (YGGFLRRQFKVVT) had the effect of 
introducing disorder into the crystal lattice.  The result was many poorly diffracting 
crystals being mounted for collection.  It made no difference which TOP construct was 
used or what soak conditions were tried.  However, we were persistent with the nine 
residue substrate and eventually determined structures from relatively resilient crystals 
without seriously damaged lattices.  This could be interpreted several ways, but one 
possibility is that the dynorphin B sequence is particularly good at inducing closure of 
TOP’s large interdomain cleft.  This substrate might be a good tool during crystallization 
screens to lock inactivated TOP in its closed structure.  
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Non-peptide inhibitor soaks 
 Many TOP and neurolysin inhibitors have been developed and those that were 
available to us were soaked into TOP crystals in much the same way as peptides.  
Previous work in the lab attempting to soak crystals in inhibitor were ended when the 
crystals disintegrated.  This was thought to be an indication of large conformational 
changes induced by the inhibitors [104].  However, in my work, TOP crystals were 
successfully soaked in concentrated solutions of inhibitors without dissolving or 
becoming disordered (Table 3.4).  The key was to carefully control the pH of soaking 
solutions as inhibitors are generally provided in a form that results in acidification of 
solutions. 
 Despite preserving the crystal quality during soaking in inhibitor solutions, no 
clearly identifiable density for any of the inhibitors could be seen in the resulting 
structures.  In the case of phosphinic compounds 3 and 5 (predicted MW = 766.8 and 
MW = 678.7 respectively) the true identity of the molecules is doubtful since mass 
spectrometry yielded masses of 503.2 and 697.3 for the inhibitors.  But in the case of 
“Mia” (aka C28), cFP-AAF-pAB, and phosphinic compound 6 the identity of the 
molecules is certain.  The lack of complex formation with these high affinity inhibitors is 
disconcerting.  It may be due to the crystal lattice imposing the open conformation on 
TOP molecules in the crystal, but more experiments are necessary to be certain. 
Substrate fragments RPKLK and RPYIL 
  Dynorphin A(9-13) and neurotensin (9-13) were soaked into crystals to test the 
effects of leaving out residues N-terminal to the cleavage site.  Structures yielded 
difference electron density corresponding to the expected fragments (Figure 3.26).   
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 The product fragment dynorphin A(9-13) interacts in the same register on domain 
I as the full thirteen residue substrate does.  This is consistent with the similar binding 
affinity seen for dynorphin A(1-13) and dynorphin A(9-13) in competitive inhibition 
assays [104].  However, the structure with dynorphin A(9-13) also shows that a second 
dynorphin A(9-13) molecule binds to domain II through a variety of interactions 
including Zn ion coordination (Figure 3.27).   
 Similarly the neurotensin (9-13) fragment binds to domain II and coordinates the 
Zn ion (Figure 3.28).  But unlike the full length neurotensin the fragment gives rise to 
electron density at the domain I site only in subsites 2 and 3, and the observed density is 
not well defined.  Difference density of neurotensin (9-13) after initial rigid body 
refinement with unliganded TOP is clearly displaced compared to full-length neurotensin 
(Figure 3.26c).  Furthermore, the fragment only partly induces the His600 rotamer shift 
and none of the Tyr605/Arg498 movement seen with full-length neurotensin and other 
fully bound peptides.  This is perhaps not surprising given that Tyr605 normally 
hydrogen bonds to the backbone carbonyl of Arg8, which is missing in this short 
fragment.  Since the expected full-length neurotensin density is seen with other C-
truncated TOP structures (without any EDTA soaking) this eliminates the possibility that 
former neurotensin structures might have been cleavage products left over from residual 
activity [104].  More importantly, it may indicate a role for the unseen N-terminal 
residues of neurotensin even in initial substrate binding to the open form of TOP. 
 In general, interaction primarily with residues C-terminal to the scissile bond in 
the open conformation of TOP has consequences for the catalytic cycle of the enzyme. 
After hydrolysis and resumption of the open enzyme conformation, the N-terminal 
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product fragment likely diffuses rapidly out of the central channel.  The C-terminal 
fragment, however, will still be bound nearly as tightly as the full length peptide. It 
seems, then, that the release of the C-terminal product fragment is likely rate limiting for 
many or all substrates.  In the case of dynorphin A(1-13) which is a reported inhibitor of 
TOP [104], the C-terminal product clearly binds so tightly as to effectively inhibit the 
enzyme.  Given the observed binding of some peptides to domain II, it is also possible 
that some products bind near the active site in a way that would also inhibit the enzyme, 
potentially further complicating the catalytic cycle.  In that sense, it is tempting to 
speculate that the faster turnover rates seen for substrates with shorter C-terminal product 
fragments [125] is due to lack of binding affinity between those product fragments and 
domain I or domain II.   
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Table 3.1  Crystallographic statistics for unliganded dual truncated 
TOP    
 
   
Data collection1   
Space group P212121  
Cell dimensions     
    a, b, c (Å) 77.9, 103.1, 106.2  
    α, β, γ  (°)  90, 90, 90  
Resolution (Å) 2.00(2.00-2.07)  
Rsym  .096(.560)  
I / σI 15.2(1.9)  
Completeness (%) 99.3(97.0)  
Redundancy 4.9(4.4)  
   
Refinement   
Resolution (Å) 2.00-43.0  
No. reflections  54365  
Rwork / Rfree .1804/.2204  
No. atoms   
    Protein 5338  
    Ligand/ion 1  
    Water 482  
B-factors   
    Protein 29.4  
    Ligand n/a  
    Water 36.1  
r.m.s. deviations   
    Bond lengths (Å) .006  
    Bond angles (°) .984  
1. Single crystal.  2. Values in parentheses are for highest-resolution shell. 
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Table 3.2  Substrate soaks with N truncated TOP 
Peptide Sequence and modifications Date collected Resolution (Ao) Activity control Result 
adrenorphin YGGFM-RRV-NH2 Dec-09 2.17 no Zn Good density along domain II 
angiotensin I DRVYIHP-FHL Apr-10 2.10 Zn Ambiguous density 
angiotensin II DR-VYIHPF Apr-10 1.97 Zn Very good density domain I 
beta amyloid 1-42 DAGFGHD……...LMVGGVV Oct-09 2.38 Zn No substrate density 
bradykinin RPPGF-SPFR Aug-10 1.80 Zn Good density along domain I 
dynorphin A 1-8 YGGFL-R-RI Dec-10 2.45 Zn Very good density domain I 
dynorphin A 1-8 YGGFL-R-RI Aug-11 2.20 no Zn Good density domain I 
dynorphin A 1-8 D8 YGGFL-R-RD Mar-09 2.00 Zn Very good density domain I 
dynorphin A 1-13 YGGFL-RRI-RPKLK Nov-08 1.97 no Zn Very good density domain I 
dynorphin A 1-17 YGGFL-RRIRPKLKWDNQ Oct-09 1.97 Zn Ambiguous density 
dynorphin B 1-9 YGGFLR-RQF Jun-09 2.24 Zn Good density domain I 
dynorphin B 1-9 YGGFLR-RQF Oct-09 2.10 no Zn Good density domain I 
hemopressin PVNF-K-F-LSH Oct-09 2.28 no Zn Too little density 
lut. horm. rel. horm. (LHRH) EH-WSY-GLRPG-OH Dec-09 1.80 Zn Too little density 
lut. horm. rel. horm. (LHRH) EH-WSY-GLRPG-NH2 Apr-10 2.60 no Zn Too little density 
neurotensin ELYENKPR-RPYIL Dec-09 2.36 Zn Good density domain I 
peptidylprolyl isomerase A (PPI) ELFADKVPKTA-ENFR Aug-10 2.50 Zn Too little density 
proctolin RYLPT Nov-08 1.83 Zn Ambiguous density 
somatostatin AGCKN-F-FWKT-FTSC Jun-09 2.07 Zn Too little density 
Substance P RPKPQ-QF-F-GLM-NH2 Mar-09 1.92 no Zn No substrate density 
eukaryotic transl. init. factor 5a (TIF) SAMTEEAAVAIK-AMAK Apr-10 3.00 Zn Too little density 
vaso. intest. peptide (VIP) HSEAVFTDNYTRLRKQMAVKKYLNSILN Jun-09 2.03 Zn Too little density 
No substrate none Aug-10 2.30 Zn No substrate density 
*Each structure summarized here represents the best of multiple structures taken on multiple occasions.  Most sequences 
exhibited at least a small amount of difference density in the binding site located on domain I, but achieving high enough 
occupancy to model the substrate unambiguously occurred only in fewer than half of cases. 
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Table 3.3  Substrate soaks with dual truncated TOP 
Ligand Sequence and modifications Date collected Resolution (Ao) Domain I binding? Domain II binding? 
adrenorphin YGGFM-RRV-NH2 Feb-12 2.45 C-terminal, ambiguous registration No 
angiotensin II DR-VYIHPF Aug-11 2.50 Good density domain I No 
bradykinin RPPGF-SPFR Oct-11 2.20 Good density domain I No 
dynorphin A 1-8 YGGFL-R-RI Oct-11 2.90 Good density domain I No 
dynorphin A 1-13 YGGFL-RRI-RPKLK Jun-11 3.00 Good density domain I No 
dynorphin B 1-9 YGGFLR-RQF Dec-11 2.80 Good density domain I No 
dynorphin A 9-13 RPKLK Jun-12 2.80 Good density  Good density 
IgG4 DSDGSFFLY Jul-12 2.50 Good density OK density 
lut. horm. rel. horm. (LHRH) EH-WSY-GLRPG-NH2 Aug-11 3.00 Too little density No - but Zn displaced 
MHC epitope Pb SYIPSAEKI Jun-12 2.25 Too little density No 
MHC epitope MAGE-1 EADPTGHSY Jun-12 2.70 C-terminal, ambiguous registration No 
neurotensin 1-13 ELYENKPR-RPYIL Aug-11 3.10 Good density  ?? 
neurotensin 9-13 RPYIL Feb-12 2.40 Novel, ambiguous, binding Good density 
none none Dec-11 2.00 No No 
phosphinic compound 6 MW = 452.2 Dec-11 2.40 No No 
Somatostatin AGCKN-F-FWKT-FTSC Dec-11 2.50 No No 
Substance P RPKPQ-QF-F-GLM-NH2 Dec-11 2.40 No No 
 *Each structure summarized here represents the best (in terms of substrate occupancy) of multiple attempts. 
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Table 3.4  TOP inhibitor soaks attempted 
TOP construct Inhibitor Date collected Resolution Concentration Time Identity confirmed? 
Active, N truncated "Mia" or "C28" Mar-12 1.90 ~.1mM 45min Made from powder 
Active, N truncated cFP-AAF-pAB Mar-12 2.00 ~5mM 45min Made from powder 
E474A, N truncated phosphinic cmp 3 Dec-10 2.65 2mM 45min MW by MS/MS = 503.2 
E474A, N truncated phosphinic cmp 5 Dec-10 3.00 2mM 30min MW by MS/MS = 697.3 
E474A, N truncated phosphinic cmp 6 Dec-10 2.10 2mM 75min MW by MS/MS = 452.2 
E474A, dual truncated phosphinic cmp 6 Dec-11 2.40 2mM 5min MW by MS/MS = 452.2 
*Only phosphinic compound 6 structure had noteworthy electron density in the binding site. 
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Table 3.5  N truncated TOP structure statistics 
 angiotensin 
II 
adrenorphin bradykinin dynorphin 
A(1-8) 
dynorphin 
A(1-8) D8 
dynorphin 
A(1-13) 
dynorphin 
B(1-9) 
neurotensin 
Resolution(Ao) 1.97(1.97-2.04) 2.20(2.20-
2.28) 
1.80(1.80-
1.86) 
2.00(2.00-
2.07) 
2.00(2.00-
2.07) 
1.90(1.90-
1.97) 
2.10(2.10-
2.18) 
2.33(2.33-
2.41) 
Reflections 55860 38749 73337 50512 55363 53789 44282 32215 
Rsym .092(.705) .112(.646 ) .060(.569) .087(.527) .090 (.614 ) .076 (.517 ) .101(.564) .126(.595 ) 
I/σI 15.5(2.2) 12.4(2.11) 22.2(2.81) 15.3(2.0) 15.7(2.74) 17.4(2.51) 10.5(2.62) 11.3(2.08) 
Completeness 99.7(99.3) 95.3(97.2) 98.2() 95.6(82.9) 99.8(99.1) 94.3(90.6) 96.7(98.3) 99.7(97.7) 
Redundancy 4.8(4.5) 5.1(4.8) 5.0(4.9) 4.9(4.0) 5.5(4.2) 4.9(4.0) 5.1(5.1) 4.5(3.4) 
R/Rfree .1998 / .2374 .1965/.2415 .1789/.2055 .1934 / 
.2335 
.1939/.2272 .2015/.2333 .2061/.2411 .1937/.2279 
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Table 3.6  Dual truncated TOP structure statistics 
 
 
 
 
 angiotensin 
II 
adrenorphin bradykinin dynorphin 
A(1-8) 
dynorphin 
A(1-13) 
dynorphin 
B(1-9) 
neurotensin IgG4 RPKLK RPYIL 
Resolution(Ao) 2.50(2.50-
2.59) 
2.40(2.40-
2.49) 
2.20(2.20-
2.28) 
2.90(2.90-
3.00) 
3.00(3.00-
3.11) 
2.80(2.80-
2.90) 
3.10(3.10-
3.21) 
2.50 (2.50-
2.59) 
2.80(2.80-
2.90) 
2.45(2.45-
2.54) 
Reflections 27908 32260 39864 16745 15962 20092 14945 25900 19408 28331 
Rsym .081(.356) .090(.389) .075(.378) .113 (.405) .076 (.517 ) .141 (.536) .142 (.458) .118(.635) .109(.503) .078(.540) 
I/σI 13.4(2.18) 15.6(2.5) 16.6(2.88) 10.3(2.32) 3.46(2.38) 11.4(1.9) 8.41(2.04) 12.7(2.18) 11.8(2.23) 18.9(2.47) 
Completeness 90.0(97.1) 98.8(94.0) 95.1(88.6) 90.4(93.6) 93.6(92.2) 98.6(91.8) 98.0(90.6) 91.3(93.6) 94.8(87.4) 93.7(92.7) 
Redundancy 3.6(3.3) 4.3(3.8) 4.3(4.3) 4.0(3.9) 4.5(4.8) 5.4(4.1) 3.3(3.5) 4.9(4.4) 5.0(4.9) 5.1(4.4) 
R/Rfree .1948/.2484 .1802 / .2205 .1948/.2484 .2010/.2498 .2006/.2319 .1951/.2437 .1893/.2400 .1916/.2469  .1935/.2503 .1893/.2392 
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Table 3.7  Interactions formed between the TOP binding site(s) and substrates. 
Substrate 
Complex 
Coordinates used Sequence 
modeled 
Salt 
bridges  
H-bonds 
mainchain  
H-bonds 
side 
chains  
Peptide 
interfacial 
surface 
area (A2)  
Total 
∆ 
ASA 
(A2) 
Energy of 
solvation 
(kcal/mol) 
Adrenorphin  adren_e_s_dec09_refine_13.pdb 
 
AARRV 01 3 2 509(57%) 9922 -.6  
Angiotensin 
II  
ang2_edta_refine_11-coot-0.pdb DRVAIHPF 4 
(R338/R553, 
E469/E509)  
4  0  822(67%)  1451 - 5.9* 
Bradykinin  brady_e_aug10_refine_20.pdb 
 
ASPFA 
 
2 
(R338/R553)  
6  0  442(58%)  869 -6.0  
Dynorphin A 
(1-8)  
top_dyn8_e_refine_20.pdb 
 
GFARRI 3 
(R338/R553,
E616)  
6 2  593(54%)  1123 -2.3  
Dynorphin A 
(1-13) 
dyn13_edta_refine_1 .pdb 
 
ARPKLA 3 
(R338/R553,
E616) 
6 0 532(50%) 1038 -3.9 
Dynorphin B 
(1-9)  
top679_dynb9_dec11_refine_10.
pdb 
 
AAARQA 3 
(R338/R553, 
E616) 
6 0 548(55%) 1029 -2.0 
IgG4  top679_igg4_1_jul12_refine_4.p
db 
ASDGSAALY 1(R553) 6 2 693(56%) 1211 -2.9* 
Neurotensin  top_nt_dec09_refine_5 ARAPYIL 1(R553)  7 0 650(58%)  1240 -5.6 
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Table 3.7  continued  
Peptide  
complex or 
model 
Coordinates used Sequence 
modeled 
Salt 
bridges  
H-bonds 
mainchain  
H-bonds 
side 
chains  
Peptide ∆ 
ASA (A2)  
Total ∆ 
ASA (A2) 
Energy of 
solvation 
(kcal/mol) 
Domain II 
adrenorphin 
adren_e_s_dec09_ref
ine_13.pdb 
 
FMRRV 0 5 2 647(67%) 990 -4.5 
Domain II 
dynorphin A 
(9-13) 
top679_rpklk_jun12
_refine_5.pdb 
 
RPKLK 3(D83,D102,H
473) 
4 2 588(62%) 976 -1.0* 
Domain II 
neurotensin 
(9-13) 
top679_RPYIL_feb1
2_refine_9.pdb 
 
RPYIL 3(D83,D102, 
H473) 
5 5 55.8(67%) 901 -1.6* 
Domain I 
dynorphin A 
(9-13) 
top679_rpklk_jun12
_refine_5.pdb 
 
RPKLK 3(R338/553, 
E616) 
7 0 498(54%) 903 -2.2 
TOP C-
terminal 
top_Cterm_dyn8d8_
2_refine_4.pdb 
 
GCEPEPQVA 0 6 1 580(48%) 975 -8.4 
1Salt bridges and hydrogen bonds were counted using COOT.  A cutoff of 3.5 Ao was used for salt bridges and hydrogen bonds.  In the 
case of bifurcated interactions, bonds were counted up to twice.  2Changes in accessible surface area and energies of solvation were 
calculated using the PDBe PISA webserver.  74A2 buried TOP surface and -1.2 kcal/mol energy of solvation were added where 
appropriate due to 599-611 loop rearrangement.  *No adjustments made for 599-611 rearrangement or Zn coordination 
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Figure 3.1  C-terminus of symmetry related TOP. a) C-terminus of a neighboring 
molecule forms intermolecular interactions near the 599-611 loop and at the active site 
Zn.  Dynorphin A(1-8) Asp8  (March 2009) soaked crystal was used to model additional, 
typically disordered, TOP residues 682-689 that yielded good density.  b) Model of TOP 
C-terminus using Tyr605 to represent the conformational change in the 599-611 loop. 
Unliganded N truncated TOP model is in orange, the unliganded dual truncated structure 
is in white, and the liganded dual truncated structure with dynorphin A(1-8) is in blue. 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
 
 
(b) 
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Figure 3.2  Length of disordered residues. Twelve disordered residues are sufficient to 
reach the substrate binding site on domain I from a neighboring TOP molecule.  A 
ribbons view of TOP is in gray, a neighboring TOP molecule is in green, and a modeled 
conformation for the C-terminal residues is in red.  
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Figure 3.3  Activity of truncated constructs. Dual truncated TOP (blue) activity 
is comparable to N truncated TOP (red).  The assay was carried out using a 
quenched fluorogenic neurotensin substrate and following the increase in 
fluorescence generated by substrate cleavage over time.  
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Figure 3.4  Previously unreported cleavage sites. a) Mass spectrum of angiotensin II 
fragments indicating cleavage at the R-V bond b) Mass spectrum of dynorphin B(1-9) 
indicating cleavage at the R-R bond.  Samples were measured after 1hr incubation with 
active N truncated TOP. 
(a)  
 
 
(b)  
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Figure 3.5 Example of a substrate bound to TOP.  TOP is shown as gray cartoon with 
the HEXXH motif and Zn cofactor highlighted.  Neurotensin is shown as orange sticks 
surrounded by its corresponding 2Fo - Fc density map.  Density is displayed at 1σ. 
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Figure 3.7  Complexes that formed with domain II. Orange background represents 
residues with clear side chain density while yellow represents sequences with only 
backbone visible.  Red dashes indicate reported TOP cleavage sites.  The dashed line 
indicates where substrates span the interdomain cleft.   
Figure 3.6  Complexes that formed with domain I.   Orange background indicates 
residues with clear side chain density while yellow represents sequences with only 
backbone visible.  Red dashes indicate reported TOP cleavage sites.  Sequences have 
been aligned based on the bond cleaved by TOP.   
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(a) adrenorphin  
 
 
(b) angiotensin II  
 
 
(c) bradykinin  
 
 
(d) dynorphin A(1-8)  
 
 
(f) dynorphin A(1-13)  
 
 
(e) dynorphin A(1-8) D8 
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Figure 3.8  FoFc maps from N truncated TOP complexes.  Final refined models 
shown in stick representation are superposed onto FoFc difference maps generated from 
initial rigid body refinement with the empty protein model.  FoFc density maps are 
displayed at 2σ cutoff level. 
(g) dynorphin B(1-9)  (h) neurotensin 
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(a) adrenorphin   (b) angiotensin II   
(c) bradykinin   (d) dynorphin A(1-8)   
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Figure 3.9  2FoFc maps of N truncated TOP complexes.  2FoFc maps from N truncated 
TOP complexes are displayed at 1σ.  Final refined models are shown in stick 
representation.  The maps were generated after refinement was complete.  
 
(f) dynorphin A(1-13) 
(g) dynorphin B(1-9)   (h) neurotensin   
(e) dynorphin A(1-8) D8   
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Figure 3.10  Dual truncated TOP ligand maps.  Substrates are represented as orange sticks.  
2fofc densities of substrates displayed at 1 sigma.  These are final refined models.  Note: 
models were left incomplete at the point where density became unreliable.  
(a) angiotensin II  (b) bradykinin 
(c) dynorphin A(1-8)  (d) dynorphin A(1-13)  
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Figure 3.10  continued.  Substrates are represented as orange sticks.  2FoFc densities 
of substrates displayed at 1 sigma.  These are final refined models.  Note: models were 
left incomplete at the point where density became unreliable.  
(f) Immunoglobulin G4 (279-287) 
(g) neurotensin  
(e) dynorphin B(1-9)  
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Figure 3.11  Apoenzyme controls. TOP N15_C2S_E474A/C427S structures were 
refined with a Zn ion in the model.  The resulting 2FoFc density of refined structures is 
displayed at 1 sigma.  Left panel:  no Zn ion removal.  Right panel: Zn ion removal.    
dynorphin A(1-8)   
dynorphin A(1-13)  dynorphin A(1-13) no Zn  
dynorphin A(1-8) no Zn   
dynorphin B(1-9) no Zn  dynorphin B(1-9)  
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Figure 3.12  Fast Zn removal with LHRH + EDTA. Electron density after initial 
rigid body refinement with a Zn ion (yellow sphere) included in model.  Blue = 2fofc 
density at 1.0 sigma, red = fofc density at -2.0 sigma   
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Figure 3.13  Additional adrenorphin binding site after Zn removal.  a) Two 
adrenorphins bind, one on each domain.  b) Domain II density is clearly seen lying along 
the beta sheet and the substrate sequence FMRRV can be modeled with the (amidated) C-
terminal lying where the Zn would have been.  His477 is disturbed and the Zn is gone 
from the active site.  The C-terminal valine takes advantage of the hydrophobic surface 
created by the E474A mutation. 
 
 
 
 
 
 
(b)  
 
(a)  
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Figure 3.14  Superposition of standard substrate complexes.  Domain I binding 
substrate complexes excluding angiotensin II, immunoglobulin 4, and fragment 
complexes are superposed on one another.  a) Fully refined substrate models are show in 
stick representation.  Enzyme surface taken from dynorphin A(1-13) complex’s surface.  
Important polar surface residues also shown in sticks.  Yellow surface indicates important 
hydrophobic or aromatic surfaces.  dynorphin A(1-13) = orange, adrenorphin = dark pink, 
bradykinin = yellow, dynorphin A(1-8) = cyan, neurotensin = pink, dynorphin B(1-9) = 
green b) view looking down the mainchain axis of superposed substrates.  TOP’s flat 
binding surface on the right prevents side chain insertion.  c) same as (a) but with beta 
carbons of cleaved bonds emphasized as spheres. 
 
 
(a)  
 
(b)  
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(a) adrenorphin   
(c) dynorphin A(1-8)   
(b) bradykinin   
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Figure 3.15  Binding site interactions for standard substrate complexes. Substrate 
groups that could be placed in the structures are shown as orange sticks while TOP 
residues are white sticks.  Left panel: hydrogen bonds and ionic interactions are shown as 
dashed lines.  Right panel: TOP binding surface is shown with hydrophobic/aromatic 
residues in yellow and interacting residues as sticks within the surface. 
(d) dynorphin B(1-9)   
(e) dynorphin A(1-13)   
(f) neurotensin   
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Figure 3.16  Binding site subsites.  Dynorphin A(1-13) substrate in a stick representation.  
The surface of TOP is colored yellow to indicate hydrophobic / aromatic surfaces.  
Arg338, Arg553, Gln554, His600, Tyr605, and Glu616 side chains are modeled as sticks 
within the surface.  The locations of subsites 1, 2, and 3 are indicted by numbered circles.   
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Figure 3.17  Domain I substrate binding site and conformational shifts.  a) Ribbons 
view of TOP colored by crystallography thermal factor (yellow = high, blue = low). The 
oval indicates the helices 7,8,12 region that shows higher than average disorder.  The 
expanded view shows two superposed N-truncated TOP - dynorphin A(1-8) complex 
structures from two different crystallizations illustrating variation in the region that 
interacts with the substrate C-terminus.  b) All significant side chain conformational 
differences seen in any structure superposed into the structure of the dynorphin A(1-13) 
complex.  dynorphin A = orange ribbon, TOP = grey ribbon, moving side chains = green 
sticks. 
(a)  (b)  
(c)  
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Figure 3.18  Subsite 1. Side chains of TOP residues F550, Q554, L613, Y612, E616 are 
shown in a stick representation.  The molecular surface is shown with aromatic or 
hydrophobic portions colored yellow.  a) Residues from different substrates occupying 
subsite 1 shown in a stick representation b) Proline residues neurotensin and bradykinin in 
subsite 1 c) Lysine residue from bound dynorphin A(1-13) demonstrating the salt bridge to 
E616. Other dynorphin-like sequences also make a similar interaction.  
(c)  
(b)  (a)  
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Figure 3.19  Subsite 2.  Side chains of TOP residues R553, Q554, M594, L557, F598, and 
Y609 are shown in a stick representation.  A semitransparent view of the molecular 
surface is shown with aromatic and hydrophobic regions indicated in yellow.  a) Residues 
occupying subsite 2 from the standard binding orientation complex structures. b) Aromatic 
residues from neurotensin and bradykinin. c) Longer charged and polar residues from 
dynorphin B 1-9 and dynorphin A 1-8.  d) Hydrophobic leucine from dynorphin A(1-13).  
All substrate residues at this subsite participate in a hydrogen bond network via backbone 
interactions (dotted lines). 
(c)  (d)  
(b)  (a)  
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Figure 3.20  Subsite 3. Side chains of TOP residues R338, R553, F225, Y221, and F550 
are shown in a stick representation.  A semitransparent view of the molecular surface is 
shown with aromatic and hydrophobic regions indicated in yellow.  Aromatic or 
hydrophobic surfaces are colored yellow.  a) Residues occupying subsite 3 from the 
standard binding orientation complex structures.  b) Angiotensin II binding reorganizes 
subsite 3 with nearly the entire side chain accessible surface of F8 buried in the 
interaction.  c) The C-terminal residue of neurotensin extends into a different portion of 
subsite 3.  d) The amidated valine of adrenorphin interacts with F225 slightly displacing it 
and Y221. 
 
(c)  (d)  
(b)  (a)  
89 
 
 
 
 
 
 
 
 
Figure 3.21  Interaction of peptide C-termini with TOP.  TOP motif that interacts with 
the C-termini of bound substrate peptides consists of arginines 338 and 553.  Dynorphin 
A(1-8) = orange, angiotensin II = blue, IgG4 = purple 
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Figure 3.22  Conserved residues around subsite 3.  an * indicates positions of 
conserved residues.  Those in the helix forming subsite 3 just above TOP’s C-terminal 
recognition motif are highlighted in red (completely conserved) and yellow (conserved in 
type).   
 
 
 
 
Figure 3.23  Binding site rearrangement upon ligand binding. a) Differences in the 
599-611 loop of dual truncated TOP before (white) and after (green) binding dynorphin 
A(1-13).  His600, Gly603-Tyr605, and Arg498 are shown in stick representation, 
dynorphin A 1-13 shown as cartoon (orange) b) residues 498, 599-612 superposed for all 
substrate complexes with dual truncated TOP.  His600, Tyr605, Arg498 are shown in a 
stick representation while the remainder of 599-611 loop is cartoon.  Unliganded TOP = 
white, dynorphin A(1-13) = orange, adrenorphin = purple, angiotensin II = dark blue, 
bradykinin = yellow, dynorphin A(1-8) = cyan, neurotensin = pink, dynorphin B(1-9) = 
green 
 
(a)  (b)  
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(c)  
(b)  
(d)  
(a)  
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Figure 3.24  TOP / angiotensin II complex.  a) Overview with angiotensin II (orange 
ribbon) and TOP (grey ribbon). b) Angiotensin II (orange) binding to the domain I 
binding site.  Hydrophobic surfaces are colored yellow and relevant TOP side chains are 
shown as sticks behind the surface. c) Subsite 3 interaction. Hydrophobic / aromatic 
surfaces are colored yellow and dashes indicate ionic interactions. d) TOP residues that 
compose subsite 3 shown in a stick representation with green carbon bonds. The C-
terminal phenylalanine of the bound peptide is also shown in a stick representation. e) 
Polar interactions with angiotensin 2. Dashed lines indicate atoms that are within 
hydrogen bonding distance (<3.5A) or within range for charge-charge attraction (<4.0A)  
f) Interactions formed between the N-terminal residues of angiotensin II and TOP 
including Zn ion coordination.  
(f)  (e)  
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Figure 3.25  TOP / IgG4 complex.  a) Overview with IgG4 (orange sticks) and TOP 
(gray ribbons).  b) IgG4 (orange sticks) with FoFc density displayed at 2σ.  Zn ion is 
displayed as yellow sphere. c) Overview of IgG4 (orange sticks) crossing the 
interdomain cleft.  Relevant TOP side chains are displayed as white sticks and ionic 
or hydrogen bonds are indicated with dashed lines.  Side chains often participating in 
conformational changes are explicitly labeled. d) IgG4 (orange) binding to the 
domain I binding site.  Hydrophobic surfaces are colored yellow and relevant TOP 
side chains are shown as sticks behind the surface.   
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Figure 3.26  FoFc density of domain II ligands.  Difference electron density for 
ligands of the dynorphin A(9-13)-TOP and neurotensin(9-13)-TOP structures.  FoFc 
density at 2.0 sigma is displayed after initial rigid body replacement.  Bound peptides 
are show as orange sticks. Zn is shown as a yellow sphere. 
(a) dynorphin A(9-13) domain I  (b) dynorphin A(9-13) domain II  
(c) neurotensin(9-13) domain I*  (d) neurotensin(9-13) domain II 
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Figure 3.27  The dynorphin A(9-13)-TOP structure. a) Overview of bound peptides. 
Dynorphin A(9-13) binds to the domain I surface, interacting in the same manner the C-
terminal residues of dynorphin A(1-13).  A second molecule of the peptide binds to 
domain II.   b) Interactions with the domain II binding site.  Aromatic/hydrophobic 
surfaces are colored yellow and dashed lines indicate hydrogen bonds.  Coordination of 
the active site Zn ion aids in binding.  orange sticks = dynorphin A(9-13) domain I,  
blue sticks = dynorphin A(9-13) domain II. 
(a)  (b)  
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Figure 3.28  Neurotensin (9-13).  a) Binding to across the TOP channel. The peptide is 
shown in a stick representation and aromatic/hydrophobic portions of the enzyme 
surface are in yellow. The zinc ion is shown as a yellow sphere. b) Comparison with 
dynorphin A(9-13) binding. Superimposed peptides structures are shown in a stick 
representation. The C-terminal product fragment neurotensin (9-13) binds to domain II 
similar to dynorphin A(9-13). orange = neurotensin (9-13),  blue = dynorphin A(9-13) 
(a)  (b)  
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CHAPTER FOUR: Thermodynamics of TOP binding 
 Much of the work done to determine the dissociation constant and catalytic 
efficiency of TOP has used quenched fluorescent substrates.  While these substrates may 
mimic the corresponding native substrate peptide in most cases, there is always a 
possibility that the bulky fluorescent moieties may disrupt normal binding.  In order to 
more accurately determine binding constants as well to more completely characterize the 
energetics of peptide binding to TOP, I used isothermal titration calorimetry (ITC) to 
investigate substrate binding. Here I report thermodynamic data for a number of 
substrate-TOP interactions performed in Tris buffer that are useful for calculating binding 
constants as well as an in-depth thermodynamic analysis of the TOP-dynorphin A(1-13) 
interaction.   
 With ITC the enthalpic and entropic contributions to binding energetics can be 
estimated;  however, a complicating factor is a change in enzyme-substrate complex 
protonation state.  If protons are given to or taken from the buffering solution upon 
enzyme-substrate complex formation, the heat observed contains a component due to the 
enthalpy of buffer ionization.  Based on a series of experiments with buffers having a 
range of ionization enthalpies (ionization enthalpies from [126]), it appears that proton 
release upon binding and subsequent ionization of the buffer makes a major contribution 
to the apparent enthalpy of binding of dynorphin A(1-13) to TOP (Figure 4.2).  Plotting 
the change in enthalpy as a function of buffer ionization gives a slope of -0.55 indicating 
0.55 protons released during titration with the peptide.  This might be explained in terms 
of the conformational change observed in His600 upon ligand interaction (Figure 4.2e).  
The pKa of His600 was calculated in both the unliganded dual truncated TOP structure as 
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well as the dynorphin A(1-13) bound structure using the PROPKA webserver [127].  In 
the unliganded structure it has a calculated pKa of 7.3, but in the dynorphin A(1-13) 
structure the pKa is only 3.9.  At a pH of 7.5 this calculated change would result in 
His600 losing 0.4 protons - not far from the experimentally observed value of 0.55. 
 Another complicating factor in ITC experiments is competing binding reactions.  
Great care was taken to purchase pure peptides and use only TOP purified to 
homogeneity in ITC experiments.  Despite this care, our recombinant TOP was only able 
to bind 50-70% of the expected substrate resulting in saturation at molar ratios between 
0.5 and 0.7.  Since crystal structures showed the propensity for TOP to bind its own 
disordered C-terminus I hypothesized that this interaction might compete for some of 
TOP’s binding sites.  However, this hypothesis proved incorrect since dual truncated 
TOP behaves much the same as N-truncated TOP (Figure 4.3).  The apparent lack of 
binding sites could be an indication that TOP carries resistant peptides with it through 
purification.  Another explanation might be that our peptide is contaminated with peptide 
sequences without a tyrosine resulting in decreased absorbance at 280 nm and 
underestimation of the actual substrate concentration.  More troubleshooting would be 
necessary to fully understand why recombinant TOP saturates at a low molar ratio in our 
ITC experiments. 
Dynorphin A(1-13) binding 
 In order to preserve substrates in their full length ITC experiments utilized N-
truncated or dual-truncated TOP with the active site E474A mutation.  Controls carried 
out using wild-type TOP and E474A TOP with or without EDTA confirmed the 
effectiveness of the E474A mutation in preventing significant peptide hydrolysis during 
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the course of the calorimetry experiments (Figure 4.1). By using dynorphin A(1-13) as a 
model ligand and subtracting the enthalpy of binding associated with buffer ionization it 
can be shown that ligand binding is accompanied by a favorable change in entropy of 1.6 
kcal/mol and favorable enthalpy change of -1.1 kcal/mol (Table 4.1).  Weak interactions 
such as hydrogen bonds and Van der Waal’s interactions are associated with relatively 
small enthalpic contributions compared to ionic interactions.  These ITC results are 
therefore consistent with binding driven mainly by water release and weak interactions 
such as van der Waal’s as seen in the crystal structure of dynorphin A(1-13). The 
hydrogen bonds formed in the TOP-dynorphin A(1-13) structure would also be formed to 
solvent in the free TOP and free substrate state likely reducing their enthalpic effect in 
peptide binding to TOP. 
Salt effects on dynorphin A(1-13) binding 
 Varying the ionic strength over the range 60-210 mM by altering sodium chloride 
concentration gave more than a four fold increase in observed binding affinity by ITC 
(Figure 4.4 and Table 4.2).  This indicates the release of water or ions during complex 
formation [128].   There are three ordered waters displaced from TOP’s surface in the 
dynorphin A(1-13) complex structure, but release of these three water molecules alone 
would not be sufficient to cause the observed change in binding affinity, since binding 
varies as 0.16 x #H2O released x [salt(M)] [128].  The dependence on ionic strength most 
likely is also caused by release of water from the peptide during binding.  Also, it is 
possible that TOP in solution may close around dynorphin A(1-13) in a way not seen in 
the crystal structure resulting in the release of water and/or ions from other regions of the 
enzyme surface. 
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Angiotensin II, adrenorphin, and neurotensin binding 
 The binding of three other substrates was also examined by ITC.  Angiotensin II, 
adrenorphin, and neurotensin, all bind with different affinities, but with similar 
stoichiometry and enthalpy / entropy breakdowns as dynorphin A(1-13) (Table 4.1 and 
Figure 4.5).  It is likely that these substrate peptides release protons during complex 
formation in the same manner as dynorphin A(1-13), therefore further experiments using 
different buffers are necessary to accurately characterize the enthalpic and entropic 
contributions to their binding.  
C-terminal product fragment binding 
 Synthesized peptides corresponding to the C-terminal fragments of dynorphin 
A(1-13) (dynorphin A(9-13), RPKLK) and neurotensin (neurotensin (9-13), RPYIL) 
yielded very different enthalpic and entropic components than those determined for the 
full length peptides (Figure 4.6).  In particular, the binding of both peptides produced an 
unfavorable enthalpic term. Since both peptides are known to bind at a second site on the 
enzyme, it is possible that this complication is responsible for the observed difference in 
enthalpy of binding. 
 Interestingly, the C-terminal portion of adrenorphin also binds at two sites like 
RPYIL and RPKLK, but only when the Zn ion is removed.  ITC characterization of 
adrenorphin binding to TOP after removing the active site Zn ion with EDTA shows a 
typical, favorable enthalpy of binding (Figure 4.5).  This result suggests that the 
unfavorable enthalpic term for binding of dynorphin A(9-13) and neurotensin (9-13) may 
be due to their interaction with the Zn ion.  Displacement of the water molecule normally 
coordinating the Zn ion may play a role.  This water is deprotonated to some extent in the 
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unliganded structure [129].  Its release would therefore cause proton release from the Tris 
buffer used for these experiments, an enthalpically unfavorable process (7.4 kcal/mol).  
These experiments should be repeated with other buffers to test this possibility. It also 
might be interesting to determine if Tris can be as a thermodynamic probe for 
displacement of the Zn coordinated water by a given ligand as is expected for many 
inhibitors designed to target neuropeptidase active sites [20, 31, 130]. 
 It is not clear from these experiments what, if any, thermodynamic contributions 
are made by closure of TOP’s interdomain cleft.  Therefore, it is not possible to 
positively link any of the interactions seen in TOP-substrate complexes to the values 
measured by ITC.  However, in a broad sense, the thermodynamic characteristics of 
TOP-substrate binding are consistent with the binding interactions seen in the crystal 
structures.  It appears that at least for dynorphin A(1-13) the release of water from the 
ligand and binding surface is likely to contribute significantly to the interaction, and that 
polar effects (van der Waals contacts and hydrogen bonds) make only a roughly similar 
contribution.   
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Table 4.1  Thermodynamic binding parameters of substrates. 
 
Ligand1 Kd (uM) ∆H (kcal/mole) 
∆TS 
(kcal/mole) 
angiotensin II 8.8 -4.6 2.4 
adrenorphin 0.35 -8.9 0.1 
dynorphin A(1-13) 0.17 -7.5(-1.1)2 1.9(1.6)2 
neurotensin 10.33 -16.0 -9.1 
 
1Dynorphin A(1-13) was most thoroughly determined.   
2Intrinsic enthalpy in parenthesis is the apparent enthalpy seen in Tris buffer minus heat 
due to buffer protonation.  
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Table 4.2  Dynorphin A(1-13) binding versus ionic strength 
Total ionic strength1 Kd (uM) H (kcal/mole) 
∆TS 
(kcal/mole) 
60mM 0.505 -18.0 -9.3 
90mM 0.386 -15.4 -6.5 
150mM 0.162 -9.7 -.2 
210mM 0.116 -8.6 1.0 
 
1Conditions were 50 mM Tris pH 7.5, 5 mM BME, 0.1 mM ZnCl2, and 10-160 mM 
NaCl. 
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Figure 4.1  Controls for activity during calorimetry.  a) Heats of injection versus 
molar ratio and enthalpy versus molar ratio dynorphin A(1-13) titrated into E474A TOP 
without any EDTA soak b) Dynorphin A(1-13) versus E474A TOP after dialyzing into 
0.02 mM EDTA c) Heats of injection of dynorphin A(1-13) titrated into wild type TOP 
(blue) or E474A TOP (black).  Activity results in a failure to achieve saturation and much 
larger heats of titration.   
 
 
 
 
 
 
(a) 
(c) 
(b) 
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Figure 4.2  Deprotonation upon ligand binding. a) TOP vs dynorphin A(1-13) in 50 
mM Tris pH 7.5 b) A parallel experiment with 50 mM HEPES buffer c) Parallel 
experiment with cocadylate buffer d) Plot of enthalpy versus buffer heat of ionization. 
The slope of the plot suggests one proton released upon peptide binding. e) His600 is a 
candidate for proton release because its conformational change moves it from a relatively 
acidic to basic environment upon dynorphin A(1-13) binding. 
 
  
(a) (b) 
(c) (d) 
(e) 
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Figure 4.3  Binding of dual truncated TOP vs N-truncated TOP.  Conditions were 50 
mM Tris pH 7.5, 100 mM NaCl, 5 mM BME.  a) Titration using N-truncated TOP Kd = 
0.16 µM.  b) Titration using dual truncated TOP Kd = 0.23 µM. 
 
  
(a) (b) 
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Figure 4.4  Dynorphin A(1-13) salt series.  Binding constants are plotted as a function 
of ionic strength based on isothermal titration calorimetry of the peptide binding to TOP.   
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Figure 4.5  Variety of substrates binding to TOP. Conditions were 50 mM Tris pH 7.5, 
100 mM NaCl, 5-10 mM BME.  In the case of adrenorphin, 1 mM EDTA pre-soak was 
used to mimic crystal soaking conditions.  a) Negative control with dynorphin A(1-13) 
titrated into buffer without TOP. b) dynorphin A(1-13). c) adrenorphin. d) angiotensin II 
e) neurotensin   
 
  
(c) (d) 
(e) 
(b) (a) 
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Figure 4.6  Product fragment thermodynamics.  a) dynorphin A(1-13) b) dynorphin 
A(9-13) c) neurotensin (1-13). d) neurotensin (9-13). During neurotensin (9-13) titration 
the endothermic peaks do not show saturation indicating that they are likely due to 
mixing effects not binding. 
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CHAPTER FIVE: Development of nanoparticle test tube 
fabrication method  
Approach to nanoparticle test tube manufacture 
This is the first report of non-destructive replication being used to produce 
suspended nano test tube particles.  A number of different parameters were varied during 
development of the test tube production method including: template pore depth, diameter, 
and lattice constant, metal composition and thickness, method of metal deposition, 
solvent polarity, ionic strength, pH, and temperature, sonication method and duration.  
Not all parameters could be systematically varied for each experiment.  Most efforts 
failed to produce tube-shaped particles suspended in solution due to the difficulty of 
removing the tubes from the replication tape used as a mould to prepare them.  After 
identification of a few of the critical parameters, a remarkably simple protocol for nano 
test tube formation and suspension was developed.   
Porous aluminum oxide templates were wetted with a thin layer of acetone using 
a cotton swab.  Cellulose acetate replicating tape 0.22 mm thick was touched to the wet 
surface with minimal pressure and capillary action was responsible for drawing the 
polymer down into the pore.  After drying for 30 seconds the replicating tape was peeled 
off.   Imprinted replicating tapes were mounted on glass slides and metal(s) deposited 
using a vapor deposition technique such as sputtering.  Metal(s) were deposited at a rate 
of approximately 0.1 nm/sec and the samples spun to insure even coating.  A quartz 
thickness monitor was placed beside the samples to measure thickness during deposition, 
and total metal deposition was kept to <10 nm.  After coating the samples were cut off of 
their glass supports and immersed in a minimal volume of water in a glass vial.  Finally, 
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the glass vials containing immersed samples were sonicated for 15 min to release the 
nano test tubes from the surface. 
Critical parameters for template formation 
 Porous aluminum produced by one-step anodization of aluminum on a silicon 
wafer proved a robust template both in terms of life span and in terms of homogeneity of 
pore size.  These templates (Figure 5.1 and Figure 5.2) lasted through 100-200 
replications with a slow, predictable, decrease in pillar height (~2-2.5 nm / replication) 
and increase in pillar diameter (~0.2-0.3 nm / replication).  Commercially available 
materials were also used, but in the case of porous aluminum oxide there were clear 
advantages to making our own.  For trials with commercial material, I bought Whatman 
Anodiscs (AAO filters) and used them to make 200 nm diameter test tubes. However, this 
was a time consuming and difficult procedure because Anodiscs are designed without a 
backing and so had to be filled with epoxy and the epoxy carefully etched back prior to 
replication in order to control the pillar height.  The anodiscs also contained multiple pore 
lattices sometimes resulting in heterogenous nano test tubes with multiple diameters 
(Figure 5.3a).  
Critical parameters for pillar coating 
 Large 200 nm pillars coated with 100, 50, 30, 15, or 10 nm of aluminum or 
titanium failed to release upon sonication.  Efforts to encourage pillar breakage by tilting 
samples 45o during deposition in order to allow shadowing changed the morphology of 
test tubes to canoe shaped particles released into solution (Figure 5.3b).  Only a 3-8 nm 
coating of metal(s) deposited face-on to pillars allowed pillars to be broken into single 
tube-shaped particles during sonication (Figure 5.4).  It did not matter what method of 
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physical vapor deposition was used, both thermal evaporation and sputter coating worked 
equally well. 
Interestingly, the maximum thickness possible for the metal coating did not vary 
much for pillar lengths in the range used.  For both 250 nm long and 1000 nm long 
pillars, the maximal coating thickness for good pillar release was about 8 nm of metal.  
Even using 200 x 1 µm diameter pillars from the densely packed pores of Anodiscs did 
not significantly alter the maximum amount of metal that could be deposited.  Although it 
might be expected that shadowing by nearby pillars would prevent metal deposition at the 
base of pillars, this effect was not found in practice (Figure 5.5a-c).  This was particularly 
unexpected, since sputtering is frequently described to be a poor method for depositing at 
the base of trenches with aspect ratio >1 [131, 132].  The good metal deposition at the 
base of pillars is probably due to the continuous network formed by inter-pillar trenches 
unlike the isolated pits used in previous reports [131, 132].  In our case, TEM 
micrographs revealed that metal was deposited to 8 nm thick only on pillar tips.  The 
coating thins to about 4 nm at a point 200 nm below the tip, then thins more gradually to 
about 1 nm 800 nm below the tip (Figure 5.5).  Pillars with bases varying between 250 
nm to 1 µm in length could be coated with 8 nm of metal(s) and still converted 
successfully to nano test tubes presumably because the metal(s) at the base of these 
pillars all fell within the 1-4 nm thickness range.  Pillars only 125 nm tall were attempted, 
but failed to release after initial experiments presumably because the metal at their bases 
exceeded 4 nm thick. 
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Approaches for pillar release 
 A number of strategies for pillar release were tried, including polymer dissolution 
with solvents, sonication, heat shock, and oxidative plasma degradation of polymer 
(Figure 5.6).  Out of these only oxidative plasma degradation and sonication were 
effective.  Simple sonication in water breaks pillars off at the base provided the metal 
coating is thin enough (Figure 5.4).  In contrast, oxidative plasma etching rapidly 
degrades the replicating tape and frees the whole sheet of pillars from the surface (Figure 
5.7).  This results in release of a significant amount of undesirable flat metal surface from 
the polymer in addition to pillars.  Furthermore, release by plasma degradation still 
required sonication to break apart the sheets of pillars.  Release by plasma degradation 
might be useful in some cases where hollow tubes are desired since tubes sonicated into 
water initially are filled with polymer, but plasma etching may partly hollow out the 
inside of pillars (Figure 5.8).  In the interest of quality and simplicity, we adopted 
sonication alone as a method for pillar release.   
Quantification of suspended test tubes 
 The protocol developed here for nano test tube synthesis is simple and cost 
effective.   Each template replication takes only a minute, so large pillared surface areas 
can be produced.  Imprinting pillars on the surface potentially increases the final surface 
area by a factor between 0.5  and 7.6 depending on the density and dimensions of pores 
in the template (Table 5.1).  This surface area is only achieved if all the replicated pillars 
break off and go into suspension.  In our experience 70-90% of all pillars are released 
into suspension during sonication as quantified by cutting and weighing printed SEM 
micrographs of released pillars (Figure 5.9). 
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 For applications utilizing the surface of nanoparticles, nano test tubes are 
competitive with standard commercially available nanoparticles.  Producing 9x1010 test 
tubes (~90 cm2 of replicated template surface at the 100 nm diameter size) only requires a 
couple hours using a 4 cm2 template.  This yields the same number of particles found in 1 
mL of commercial 40 nm gold colloid as ordered from BBI (Ted Pella catalog # 15707-
20).  However, a 40 nm colloidal gold particle has only 5024 nm2 surface area.  
Depending on their dimensions each nanotube has 8 - 275 times that much surface.  So, a 
preparation of nano test tubes could carry a much larger amount of surface immobilized 
therapeutics such as enzymes. The same porous alumina template can be used to produce 
9x1010 test tubes at least five times before a new template is needed.   
 Nano test tubes have the potential to demonstrate efficacy as delivery vehicles for 
biologics, with the delivery of enzymes being a particularly promising application.  As 
catalysts, enzymes have the ability to convert large numbers of important metabolites 
over a long period of time.  An approximation of the number of nano test tubes required 
for enzyme therapy can be calculated using Elaprase enzyme therapy for 
Mucopolysaccharidosis II (Hunter syndrome) as an example [133].  This therapy requires 
administration of 0.5 micromoles of idursulfase enzyme every two weeks.  With a 
diameter of 4 nm2 per molecule a dose would cover 13000 cm2 of surface area.  
Projecting immobilization of idursulfase only on inner tube surfaces with dimensions 50 
nm x 1 µm 6400 cm2 of AAO template would be needed per dose.  Using such a large 
AAO template is impractical if the template must be remade after each synthesis.  
However, by using our non-destructive method to quickly turn out 100 secondary 
templates from a single AAO primary template, 6400 cm2 of pillars can be produced 
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relatively rapidly from only 64 cm2 of template.  This replication process could be easily 
automated by passing acetone treated tape through a roller with AAO template on its 
surface.   
Most enzyme therapeutics are quickly inactivated in the body.  Idursulfase, for 
example, has an active half-life of only 114 minutes in the bloodstream.  If enzymes 
could be stabilized through immobilization within nano test tubes they would exhibit 
active lifetimes beyond current enzyme therapies [67].  This, in turn, would allow much 
smaller doses requiring fewer nano test tubes.   
 Our nano test tube fabrication method produces tubes with walls varying between 
1-8 nm in total thickness.  Producing nano test tubes with very thin metal walls is 
attractive from a toxicity standpoint in therapeutic uses because it minimizes the amount 
of metal introduced into the body for a given surface area.  For example, if a dose of 
idursulfase were immobilized on nano test tubes with an average 3 nm thickness the 
resulting injection would contain only 2 µl total metal volume.  Once diluted in the 
bloodstream it would be well within amounts deemed innocuous for gold particles in cell 
viability assays [134].   
Advantages of gold and titanium during suspension 
 The incorporation of gold into nano test tubes has several potential advantages.  
The strong absorbance of gold allows visual and spectrophotometric quantification of 
tubual yield (Figure 5.10).  The absorbance of nano test tube suspensions per mg of gold 
was comparable to that expected based on the absorbance of standard gold colloid 
solutions, indicating close to 100% suspension.  Standard 5 nm diameter colloidal Au 
116 
 
solutions had an adsorption of 472 abs/mg-cm while the tubes had 389 abs/mg-cm.  (The 
dispersed Au nano test tube mass (.003 mg) was calculated using a sample with 3 nm 
thick gold on tube tips and presuming only 1 nm on sides with a yield of 76% pillars 
released.) 
 Incorporating gold also allowed us to follow nano test tube settling over time.  
Nano test tubes remained suspended in water in a 30 mL glass sample jar for up to twelve 
hours before noticeable settling began.  After settling to the bottom of their containers 
they were easily resuspended by 15 minutes of sonication.  The settling time after such 
re-suspension was measured by following the absorbance of a typical nano test tube 
sample at 600 nm over two weeks.  Interestingly, the test tubes settled much more slowly 
in a 1 cm plastic cuvette than in a large sample jar.  It took six days for half of the 
particles to completely settle in the cuvette (Figure 5.11).   
 During attempts to bond material to the nano test tubes, sonication after filtering 
samples was necessary to re-suspend particles washed on alumina filters.  Titanium 
coating appeared to aid in resuspension.  This advantage of titanium is likely due to the 
isoelectric point of titanium dioxide (6.0), which results in most of the groups being 
ionized in neutral solution.  Purely gold tubes lacking the repulsive charge did not 
resuspend as well, resulting in some minor sample loss during washes (Figure 2.7).   
Nano test tube homogeneity 
 Non-destructive replication yielded homogenous mixtures of nano test tube 
particles as assessed by electron microscopic inspection.  SEM micrographs show that 
nominally fifty nanometer diameter tubes vary in the range of 40-60 nm in diameter, and 
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the length of each tube varies by less than 100 nm (Figure 5.4).  The biggest challenge to 
producing homogenous test tubes is preventing pillars from being linked during metal 
deposition.  Most samples had less than 5% of nano test tubes fused in this way.  
However, some samples had as many as 50% of tubes attached to at least one neighbor.  
Fusion can occur if metal is deposited too thickly causing pillars to join together at the 
base.  Fusion also occurred sometimes at the tips or sides of pillars that were touching 
prior to metal deposition.  Using AAO templates made in the laboratory, which had more 
widely spaced pores than commercially purchased templates, resulted in much lower 
levels of linking.  Also, using a face on coating geometry, instead of coating at an angle 
to the pillar axis, was helpful in preventing pillar bending during deposition.  Uniform 
pillar bending as a result of coating at an angle, however, might provide a means of 
making curled nano test tubes [89].     
Composite nano test tubes for differential surface chemistry 
 The ability to produce layered gold/titanium nano test tubes was confirmed using 
transmission electron microscopy.  TEM images clearly show test tubes with two metal 
layers having different apparent densities, consistent with the presence of both metals 
(Figure 5.12).  Titanium oxidizes in atmospheric conditions, unlike gold which remains 
in its elemental form.  Thus, the outer surface has hydroxyl groups while the inner 
surface is lined with underivatized metal.  Gold is a potentially useful inner surface since 
there is considerable experience with linking molecules of interest to gold surfaces [135].  
Titanium is a desirable outer surface since tethers such as silanols allow macromolecule 
immobilization on titanium, potentially allowing PEGs or targeting macromolecules to be 
attached.   
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 Unfortunately, all attempts to direct surface chemistry specifically to the inner 
surface of nano test tubes were unsuccessful.  During the course of these investigations, it 
became clear that surface chemistry is possible on the outer surface of nano test tubes, but 
not the inner surface.  This strongly suggests that the polymer core is not being 
completely removed from the nano tubes and is blocking access to the inner surface.  In 
one experiment, test tubes were plasma cleaned long enough to remove more than 1 µm 
of polymer (1hr).  They were washed and soaked with acetone and dimethylformamide 
(DMF) to dissolve polymer.  Then they were burned in air at 500oC for one hour.  
Finally, they were washed in solvents again to remove any residual polymer ash.  After 
this extensive attempt at polymer removal, biotinylation attempts using a thiol-biotin 
tether resulted in significant biotin detected on tubes with gold outer surfaces.  However, 
in spite of all attempts to remove polymer no biotin was observed to attach on the gold 
lined titanium tubes, indicating the continued unavailability of inner test tube surfaces 
(Figure 5.13).   
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Table 5.1  Nano test tube surface area increases by template. 
diameter 250nm depth 500nm depth 750nm depth 1000nm depth 
50nm 0.5 0.9 1.4 1.8 
100nm 1.0 1.9 2.8 3.7 
200nm 2.2 4.0 5.8 7.6 
 
*Values are based on averaging the number of pillars/area in SEM micrographs of the 
respective template replicas then calculating their outer and inner surface areas.   
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Figure 5.1  SEM of 50 nm templates and pillars.  a) 50 nm pore diameter laboratory 
produced AAO template  b) Resulting 1 µm tall pillars. c)  500 nm tall pillars resulting 
from replicating a thinner 50 nm pore size template.   
 
 
 
 
 
 
(a) 
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Figure 5.2  100 nm and 200 nm templates and pillars.  a) 100 nm pore diameter 
laboratory produced AAO template. b) Pillars after replication of a template made similar 
to the one shown in panel a.  c) 200 nm Whatman AnodiscTM.  d) Pillars from replicating 
Whatman AnodiscTM after partially filling the pores with epoxy. 
 
 
 
Figure 5.3  Nano tentacles and nano canoes.  a) Patches of pillars replicated from 200 
nm diameter Whatman anodiscs frequently had a single, very long, tentacle sprouting 
from their top.  b) Nano test tubes (50 x 1000 nm) sputter coated with 5 nm of aluminum 
from a 45o angle.  The metal is thick on one side and missing on the other resulting in 
canoe shapes. 
 
(a) 
(d) (c) 
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Figure 5.4  Nano test tubes after suspension and filtration. Nano test tubes on 20 nm 
porous aluminum filters after release from replication tape surface by sonication. a) 50 x 
250 nm titanium test tubes. b) 50 x 500 nm test tubes. c) 50 x 1 µm test tubes. d) Close 
up of polymer filled titanium tubes. 
 
  
(a) (b) 
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Figure 5.5  Sputtered metal deposition.  This 100 nm diameter test tube was sputtered 
with nominally 4 nm gold.  In practice the gold is only 4 nm at the tip and thins to 1 nm 
along the sides of the tube.  
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Figure 5.6  SEM micrographs of unsuccessful pillar release.  a) Remaining 50 x 500 
nm pillars on a replication tape sonicated after coating with 10 nm of titanium. b) Top 
view of tubes that released during sonication but remained connected at the rims in a 
large sheet. c) Bottom view of tubes that released in a large sheet.  d) Pillars after 
attempted release by immersing coated replicas in acetone. 
 
 
 
Figure 5.7  Plasma degradation releases pillars.  200 x 500 nm replicated pillars 
subjected to 1.5 hrs of oxidative plasma etching. 
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Figure 5.8  Removing polymer from inside tubes. Tubes are shown a) before and b) 
after plasma oxidation. 
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Figure 5.9  Quantification of test tube yield.  a) SEM micrograph of a replicating tape 
surface after sonication to remove pillars.  b) Close up showing successful release 
(76.2%).  c) Close up of area of incomplete release (23.7%). 
  
23.7% 76.2%  
(a) 
(c) (b) 
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Figure 5.10  Gold nano test tube absorbance spectrum.  The absorption spectrums of 
100 nm x 1 µm test tubes at a concentration of 6.5x109 tubes/mL (0.29 cm path length).   
a) Gold-titanium hybrid test tubes showed relatively high absorption with a maximum at 
650 nm.  b) Titanium test tubes at the same concentration had negligible absorption.   
  
(a) 
(b) 
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Figure 5.11  Gold nano test tube absorbance over time.  100 nm x 1 µm nano test 
tubes composed of a 5 nm gold layer coated with 3 nm titanium were allowed to settle in 
a 1 cm cuvette.  Absorbance of the suspension at 600 nm was measured at the indicated 
time points.   
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Figure 5.12  Gold lined titanium test tubes in TEM.  a) 50 x 500 nm gold lined 
titanium test tubes. b) Close up view of a test tube showing the layers of dark (gold) and 
light (titanium) contrast. 
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Figure 5.13  Biotin immobilization on nano test tubes. a) Biotin conjugated thiol linker  
b) A representative standard curve for the Quant Tag biotin detection kit.  (A standard 
series was done in parallel with each experiment.) c) Photograph of the four most 
concentrated biotin standards followed by pure gold test tubes sample.  d) Quantification 
of biotin on each sample using Quant Tag standard curves.   
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CHAPTER SIX:  Summary and future directions 
Structural basis for TOP substrate recognition 
 A model for TOP substrate recognition and hydrolysis was developed in a 
previous dissertation from our group [104].  This model has been refined based on the 
work presented here.  Changes to the model largely stem from a more critical evaluation 
of substrate electron densities plus the introduction of a new TOP construct lacking the 
last ten C-terminal residues.  Structures with improved ligand occupancy led to the 
conclusion that adrenorphin, bradykinin, dynorphin A(1-8), and neurotensin complexes 
should be modeled with the substrate’s registration shifted to fill unexplained density at 
the C terminus.  Unfortunately, LHRH, dynorphin A(1-17), and substance P complex 
structures both in this work and in previous studies [104] had poor density that could not 
be used to unambiguously assign substrate registration in complex with TOP.  Therefore 
these structures were not included in the current analysis.  Of the previously modeled 
TOP-substrate structures, angiotensin II and dynorphin A(1-13) structures were judged in 
the correct registration, and these were carried over largely as originally modeled, with 
additional residues modeled on the N terminus of angiotensin II.  Models for 
adrenorphin, bradykinin, dynorphin A(1-8), and neurotensin have been revised, and new 
structures have been determined for dynorphin A(1-8) D8, dynorphin B(1-9), and 
immunoglobulin 4 ligands binding to TOP. 
This study identifies the unusual binding surface that TOP and similar 
neuropeptidases use to recognize their substrates, and it sheds light on the conformational 
changes associated with initial substrate binding.  We propose that unliganded TOP in its 
open form typically interacts initially with substrates through domain I at the identified 
132 
 
C-terminal binding site.  Initial binding is mediated through interactions with four to 
eight substrate residues, with the strongest interactions generally occurring with residues 
C-terminal to the scissile bond.  The broad substrate specificity of TOP is due to the 
characteristics of the binding surface (Table 6.1).  The relatively flat, carbon rich, binding 
surface that allows interactions to a wide variety of substrate sequences, which bind in an 
extended conformation.  Furthermore, differing sequences near the substrate C-termini 
are accommodated by residues that alter conformation to optimize interactions.  Side 
chains from residues of the bound peptide generally lie in shallow grooves rather than 
recognition pockets characteristic of interactions conferring specificity in proteases [136, 
137].  These binding sites are able to accommodate multiple residue types and generally 
make few specific interactions.  The backbone path of bound peptides was seen to vary 
for the different sequences, presumably the flat surface permits them to optimize 
interactions in this manner.   
The long, flat binding surface found in TOP is in contrast to sequence specific 
proteolytic enzymes such as trypsin, chymotrypsin, and matrix metalloproteases, that 
recognize specific side chains through interactions at one or two relatively deep pockets 
[136-138].  The shallowness of TOP’s subsites allows side chains to adopt a variety of 
conformations so that the substrate’s side chains can deploy in whatever way maximizes 
the burial of hydrophobic surface and forms the most van der Waal’s interactions.  
Substrates in our structures can be clearly seen taking advantage of this freedom when 
their coordinates are superposed (Figure 3.14).  Studies systematically varying the 
residues in TOP substrates or inhibitors have previously identified mild preferences for a 
basic residue at P2’ and a hydrophobic residue at P3’ [31, 43].   These preferences are 
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probably caused by Glu616 which lies at the bottom of subsite 1 and by the particularly 
hydrophobic nature of subsite 2.  TOP substrates such as dynorphin A(1-13) that are able 
to insert both a basic and hydrophobic residue at once into these two subsites might be 
expected to have a particularly low Km.   
An early study of TOP activity found that a minimum length of six residues is 
required for substrate peptides [110].  This minimal length is generally consistent with 
the findings reported in this dissertation, since between four and eight residues were 
found to be ordered at the binding site.  The structures reported here also explain to some 
extent the restriction on maximum length of peptides to about 17 residues [43, 110].  
Simple modeling of a 17 residue peptide in extended conformation with the C-terminus 
placed appropriately at the substrate-binding site, suggests that only about that many 
residues can be accommodated in the closed end of the central channel of the enzyme. It 
would be difficult for the N-terminal residues of the peptide to turn and exit the channel, 
since elements from the enzyme overhang the channel at the closed end. 
 Dual truncated TOP provided unexpected insights into the true unliganded 
structure of the TOP binding site.  Earlier structures of TOP showed His600 and Tyr605 
located in the binding surface roughly facing the open end of the central channel.  Upon 
truncation of TOP’s disordered C-terminal tail the binding site surface, most notably 
His600, Tyr605, and Arg498 was observed adopting a different conformation.  The 
apparent conformational changes illustrate the value of crystallizing TOP without the 
terminal disordered regions.   
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 Analysis of related structures of enzymes in the cowrin family reveals that all 
were crystallized with disordered regions long enough to interact with the binding site 
except for neurolysin (reviewed by [139]).  Furthermore, residues in these paralogs, with 
the exception of neurolysin, equivalent to His600 and Tyr605 in TOP have conformations 
similar to those seen in TOP when the disordered C-terminal residues are present [52, 
140-142].  It may be that cowrins tend to crystallize with their neighbor’s tail inhabiting 
their binding site which could have the dual benefit of stabilizing a relatively labile 
region during crystallization and also providing intermolecular contacts.  Neurolysin is 
the exception because it has no disordered C-terminal tail [50], and here the loop 
containing the equivalent of Tyr605 is disordered.  The substrate-binding surfaces of 
these paralogs probably adapt to substrates as the binding surface of TOP does, but it may 
be necessary to crystallize shortened constructs before the conformational change upon 
ligand binding can be visualized.   
TOP and antigen processing 
Out of the vast array of possible sequences for MHC I presentation there is a 
culling process that reduces the number of peptides that might be loaded onto MHC I 
(Figure 1.2). The trimming and culling of the antigenic peptide population in the cytosol 
is attributable to a number of cytosolic oligoendopeptidases, oligoexopeptidases, and 
aminopeptidases.  It has recently been shown that TOP, in particular, is key in limiting 
the population of peptides available for association with MHC I [15, 16, 143-145].  
Interestingly, although TOP hydrolyzes many cytosolic oligopeptides in general, against 
a pool of randomly selected MHC I antigenic peptides it performed very poorly [16].  
The lack of processivity was not due to poor affinity, since each MHC I peptide bound 
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TOP with affinities in the nanomolar to low micromolar range.  Rather, the peptides acted 
as competitive inhibitors [16, 146].  That TOP plays a role in culling out peptides for 
MHC I presentation was confirmed by T cell activation studies using specific TOP 
inhibitors.  Antigen presenting cells were transfected with hsp65 then their ability to 
induce proliferation of T cells was tested with or without addition of a specific TOP 
inhibitor (cFP-AAY-pAB) into the cytosol.  The ability of inhibitor treated cells to 
activate T cells through CD8 / MHC I antigen presentation was reduced by more than 
half [144].  TOP’s substrate binding surface, identified here, with shallow hydrophobic / 
aromatic grooves and adjustable C-terminal recognition motif suggests it is well adapted 
for hydrolyzing a large set of potentially antigenic sequences.  In addition, the structure 
of the antigenic IgG4 fragment binding to TOP as a competitive inhibitor provides one 
example of how certain sequences avoid hydrolysis and increase their chance of 
presentation on MHC I.   
Productive versus non-productive binding conformations 
 The conformations adopted by substrates on TOP’s binding surface can be 
correlated with successful processing.  The most dramatic examples of poorly processed 
peptides that yielded structures are dynorphin A(1-13), angiotensin II, and IgG4 peptides.   
In the case of dynorphin A(1-13) product inhibition by the C-terminal is likely 
responsible for inhibition of TOP.  Previous studies in this group showed that TOP 
processes dynorphin A(1-13) at least once and that peptides corresponding to the C-
terminal product fragment dynorphin A(9-13) potently inhibits TOP with a Ki of 0.4µM 
[104].  
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The structures of TOP complexed with angiotensin II and IgG4 point to a 
different explanation for their inhibitory properties.  Both angiotensin II and IgG4 bind to 
TOP in a manner that differs from a typical substrate peptide.  Instead of extending at a 
45o angle out from domain I and up towards the closed end of the central channel, they 
bridge the cleft in a direction nearly perpendicular to the channel (Figure 6.1a,b).  The 
strong Zn coordinating interactions that these two substrates form with domain II likely 
stabilize this binding orientation.  Angiotensin II coordinates Zn through the side chain of 
its N-terminal aspartate residue and also interacts with Glu469 and Glu509 through Arg2 
of the peptide (Figure 3.24).  IgG4 coordinates the Zn ion through the carbonyl carbon of 
Gly4, which displaces the catalytic water at the active site.  It also forms a charge-charge 
interaction with Arg498 through a bridging water molecule and 4-5 hydrogen bonds to 
the β6 strand of the enzyme, which is located over the active site (Figure 3.25).   
 The conformations of angiotensin II and IgG4 in the domain I binding site fail to 
induce the liganded conformation of the 599-611 loop seen in normal substrates.  If they 
bound in the normal manner, angiotensin II would form a hydrogen bond with Tyr605 
through the backbone carbonyl oxygen of Val3 and IgG4 would do the same through 
Gly4.  But this is not the case. Tyr605 remains in its extended conformation pointing into 
the channel at Asp83 instead of pointing towards the active site Zn ion (Figure 6.1c).  
 Overall, then, both angiotensin II and IgG4 bind in a manner that is incompatible 
with hydrolysis by the enzyme. Instead of binding primarily to the hydrophobic surface 
on domain I with their C-terminal residues mediating the interaction, they cross the 
interdomain cleft and interact with domain II via polar interactions and Zn ion 
coordination.  Not only are the N-termini more ordered, but the last C-terminal residue is 
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also more ordered in angiotensin II and IgG4 since in both cases the last residue interacts 
with less mobile areas of TOP’s surface (Figure 6.1d).  This partly explains good density 
seen for the whole length of these substrates and suggests that these sequences may lack 
contacts with TOP surfaces that physically destabilize the other substrates.  Furthermore, 
although these peptides coordinate the Zn ion in the open TOP complexes they do not 
form the expected geometry for hydrolysis.  Angiotensin II coordinates Zn through an 
aspartate side chain, and the closest peptide bond is located well away from the active 
site.  IgG4 interacts with the Zn ion with coordinating main chain carbonyl oxygens but 
in such a way that the catalytic water is displaced and hydrolysis cannot occur.  Thus 
these two peptides act as classic competitive inhibitors, blocking the active site 
machinery to inactivate the enzyme. 
Implications for neuropeptidase inhibitor design 
 The angiotensin II, IgG4, dynorphin A(9-13), and neurotensin (9-13) structures 
provide examples of tight binding that are instructive for designing specific TOP 
inhibitors.  In contrast to substrates that are efficiently hydrolyzed, these sequences have 
significant interactions formed with domain II as well as domain I.  Furthermore, each of 
these is seen to coordinate the active site Zn.   
 Angiotensin II binding is anchored in large part by its N-terminal aspartate and C-
terminal phenylalanine.  If angiotensin II is used as a template for inhibitor design these 
terminal anchor residues should remain the same.  However, the binding affinity might be 
improved by changing His6 to a large hydrophobic/aromatic residue in order to take 
better advantage of hydrophobic subsite 2.  Also, Val3 appears to remain solvent 
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accessible in the complex structure, so it could be changed to a small polar residue to 
improve substrate solubility.   
 Dynorphin A(9-13) and neurotensin (9-13) bind to both domains of TOP and 
either site would effectively compete for binding with other substrates (Figure 3.28).  
Both fragment structures confirm that five residues is a suitable length for binding to 
domain II.  Their binding is anchored on domain II by the C-terminal carboxylate group 
and by Arg9 so these should be conserved in inhibitors.  The structure of neurotensin (9-
13) is poorly defined on domain I and so cannot serve as a template for inhibitor design.  
The dynorphin A(9-13) structure provides opportunity for optimizing binding to both 
domains.  Lys13 may interact unfavorably with His424, and it could be converted to a 
negatively charged or polar residue to improve affinity.  Similarly, Lys11 of dynorphin 
A(9-13) may interact unfavorably with His87 on domain II; however, it forms a favorable 
interaction with Glu616 in subsite 1 of domain I.  It might be advisable to exchange it for 
a neutral hydrophobic residue such as a methionine or leucine since this would be 
favorable in the domain I interaction and less unfavorable interacting with domain II. 
 The strategy outlined would produce inhibitors for binding to both domains in the 
open form of TOP.  Fortuitously, the structure of TOP in complex with dynorphin A(9-
13) also provides an opportunity for designing longer TOP inhibitors that bind to the 
closed form.  The two peptides with sequence RPKLK interact on opposite sides of the 
cleft, and where one peptide ends the other begins.  This can be best visualized by 
dividing the two domains of TOP and superposing them on the structure of bacterial 
dicarboxypeptidase (DCP) (pdb ID 1Y79) which was solved in the closed form.  This 
simple movement carries R9 of the fragment bound on domain I to the same position as 
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K13 of the fragment bound on domain II (Figure 6.2).  A single sequence RPKLRPKLK 
can be modeled making all the same interactions as the two fragments except with the 
surrounding TOP protein closed similar to DCP.  This peptide inhibitor could then be 
improved by introducing a phosphinic group [20] between Lys5 and Arg6 to coordinate 
Zn ion and prevent cleavage.  Also, a variation of the sequence might improve binding as 
described above, by replacing Lys3 with a hydrophobic residue (ie RPMLRPKLK) to 
prevent clashes with His87. 
Domain I residues in catalysis 
  Thermolysin-like metalloenzymes such as TOP are believed to use at least one 
polar or charged residue to stabilize the anionic catalytic intermediate [147].  His600, 
Tyr605, and Tyr612 have all been shown to affect TOP catalysis with mutation of Tyr612 
having a particularly large effect [115, 148].  An important role for Tyr612 is supported 
by these structures since it is within hydrogen bonding distance of all backbone carbons 
attacked with the exception of resistant substrates such as dynorphin A(1-13) and 
angiotensin II.  However, the orientation of Tyr612 relative to the backbone must change 
during hinge closure as the carbonyl oxygen of the scissile peptide bond coordinates the 
Zn ion at the active site.  His600 and Tyr605 interact with the main chain of bound 
peptides, again consistent with mutagenesis identifying them as important in the catalytic 
cycle.  
Models for closed TOP / substrate complexes  
 As has been noted, the substrate binding seen in the crystal structures presented 
here represents an initial binding event, and a hinge-like, partial closing of the central 
channel would be required to move the bound peptide into position for hydrolysis by the 
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enzyme.  It is important to keep in mind that substrate peptide residues N-terminal to 
those ordered in the complex structures reported here would likely interact more strongly 
with the enzyme in the closed form.  Contacts with other TOP molecules in the crystal 
lattice prevent the closure from occurring in the crystals, and to date TOP has not been 
crystallized in the closed form despite extensive trials.  Other metallopeptidases in the 
TOP/neurolysin fold group have been crystallized in the closed form, however [51, 52].  
In all cases, the closed form has been seen only when the enzyme is in complex with a 
bound ligand. 
Based on the structure of the closed form of peptidyl dipeptidase (Dcp), I 
constructed a model of the closed form of TOP (Figure 6.3a).  Using this model, the 
bound neurotensin and bradykinin substrates are brought into position with the carbonyl 
group of the known scissile bond roughly in position to coordinate the zinc ion and with 
the catalytic water within the range for nucleophilic attack (Figure 6.3b).  Applying the 
same treatment to the dynorphin A(1-8), dynorphin B(1-9), and adrenorphin complexes 
shows that the peptides are not positioned for cleavage at the known scissile bond.  There 
are two possible explanations for this observation.  Either the enzyme has some 
variability in the closing hinge motion that is influenced by interactions of the peptide 
with domain II, or the bound peptide is able to shift registration in the closed form of the 
enzyme (Figure 6.4).  In the absence of closed-form TOP-ligand structures, it is not 
possible to distinguish between the two models.   
Application of nano test tubes 
I present here an efficient procedure for fabrication of nano test tubes that is 
potentially scalable for bulk manufacturing.  A long range goal of this work is to 
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encapsulate enzymes such as neuropeptidases in nano test tubes to demonstrate their 
potential utility as delivery devices for medical and industrial applications.  During the 
course of this work we attempted multiple strategies for the immobilization of enzymes 
inside nano test tubes, but without success.  It seems possible that some of the original 
polymer material used as a template in making the nano tubes is contaminating the inner 
tube surface, preventing access in attempts to derivatize that surface.  The contamination 
was apparently not fully cleaned away despite oxidative plasma cleaning, exposure to 
high temperatures, or exposure to organic solvents - all of which were tried alone or in 
combination.  Future attempts at enzyme immobilization inside nano test tubes should 
focus on using different polymers or solvents for non-destructive replication of AAO 
templates or on different metals other than gold that might bond less tightly to polymer 
during coating.  It might be possible to shake off empty test tube shells from nano pillars 
during sonication if the strength of the polymer / metal interaction were reduced. 
 In other future applications of nano test tubes, the polymer core might actually be 
used to advantage.  The idea would be to permeate therapeutic compounds into the 
polymer and then use the test tubes as timed-release delivery devices.  Many otherwise 
promising drug leads suffer from water insolubility, so nano test tubes could be used as a 
means of “nanosuspension” of otherwise insoluble drugs [149, 150].  The time course of 
release might be controlled by adjusting the length and diameter of the nano tubes.  
Importantly, the outer test tube surface, which can be derivatized, could be used to attach 
targeting molecules such as antibodies, peptides, or DNA.  It should be straightforward to 
include a therapeutic compound by simply dissolving the drug in the solvent used to wet 
the primary template.  This should result in incorporation of the drug into the polymer 
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matrix as the solvent evaporates from inside the pores of the primary template (Figure 
6.5).   
Although our goal of enzyme immobilization in nano test tubes was not realized 
the non-destructive method for template replication of nano test tubes we developed 
makes it possible to synthesize test tube shaped nanoparticles in yields up to one hundred 
fold larger than current methods.  We report the use of non-destructive template 
replication to manufacture test tube shaped nanoparticles with diameters of 50-200 nm 
and lengths of 250 nm -1 µm without modification of the synthesis method.  Shorter 
tubes only 125 nm in length could not be released, but this limit was not investigated in 
detail and it may be possible to produce tubes shorter than 250 nm long by simply using 
thinner metal coatings.  The ability to vary the aspect ratio with this technique may have 
advantages when using the particles as therapeutics or in industrial processes. The 
vacuum deposition method of forming nano test tubes is versatile allowing the 
incorporation of a number of useful materials including magnetic metals.   
Conclusion 
 In conclusion, we have greatly improved our understanding of substrate 
recognition in neuropeptidases.  By characterizing the unusual binding surfaces of a 
model neuropeptidase my work explains the mechanism for a key characteristic of this 
group, the ability to recognize a broad set of cleavage site sequences.  This work also 
adds to our understanding of peptide recognition in general, and even bears upon the 
transient protein-protein interactions that underlie many cellular processes.  
Understanding the structural basis of TOP recognition also paves the way for future 
efforts to design specific inhibitors to this important family of enzymes.  Finally, 
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characterization of TOP’s binding surfaces now allows efforts toward rational retargeting 
of the enzyme to primarily metabolize specific bioactive peptides.  Neuropeptidases 
reengineered to target particular peptides would be promising therapeutics for a variety of 
human disorders including heart disease and Alzheimer’s disease. 
I have also developed a new method for synthesis of nano test tubes, which can be 
formed in a variety of sizes and compositions.  We show that the particles retain most of 
the desirable qualities of previously synthesized nano test tubes and that yields are on the 
scale necessary for therapeutic delivery vehicles.  The increased yields from our non-
destructive replication method provide ample material for laboratory testing and provide 
natural avenues for scaling up for large scale production.  More work is necessary to 
demonstrate the efficacy of these nano test tubes in delivery of biological molecules for 
industrial and therapeutic applications. 
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Table 6.1  Binding mechanisms summary 
Mechanisms of broad substrate recognition by TOP 
 
 Relatively flat binding surface rich in carbon allows Van der Waal’s optimization  
 
Ordered waters are displaced from surface 
 
Hydrogen bonds formed mainly with  substrate backbone 
 
Shallow, multifunctional, grooves in surface accommodate side chains 
 
Adaptive C-terminal recognition motif adds plasticity in border of binding site 
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Figure 6.1  Characteristics of non-productive binding. Superposed complex structures 
of dynorphin A 1-8 (orange ribbon), angiotensin II (blue ribbon), and IgG4 (purple 
ribbon).  a) Angiotenin II is shown as orange sticks with refined 2FoFc density displayed 
at 1σ while TOP is shown as gray ribbons b) IgG4 279-287 is shown as orange sticks 
with refined 2FoFc density displayed at 1σ while TOP is shown as gray ribbons c) 
His600, and Gly603-Tyr605 of TOP are shown in the background (color coded for their 
respective ligands) along with unliganded TOP (white) d) dynorphin A(1-8) (orange 
ribbon), angiotensin II (blue ribbon), and IgG4 (purple ribbon) with the C-terminal 
residue side chain shown.  TOP is shown as a surface color coded by B factor (blue = 
lower, yellow = higher).  Arg338 and Arg553 are shown as sticks. 
 
 
 
 
(a) (b) 
(c) (d) 
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Figure 6.2  Dynorphin A(9-13) closed model.  a) TOP is shown as gray ribbons. with 
the active site highlighted.  The two fragments bound to either domain are shown as 
orange sticks (domain I) or blue sticks (domain II).  Arrows indicate the rigid movement 
modeled by independent superposition of the two domains on closed DCP structure.  b) 
Stick models of fragments after closed form modeling.  Zn is shown as a yellow sphere. 
 
 
 
 
 
 
 
 
(a) (b) 
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Figure 6.3  Closed model of active site. a) The two domains of each TOP substrate 
complex (domain I = residue #1-145, 350-543, 615-689 and domain II = residue #146-
349, 544-614) were separated then superposed independently onto the closed DCP 
structure (1y79).  The morph function in Chimera was then used to morph an open 
structure of unliganded TOP into the closed model.  Neurotensin and other substrates 
were subsequently superposed into the closed model by alignment with domain I.  b) 
Closeup of the active site geometry.  The catalytic water (red) in the closed model is 
within range for nucleophilic attack on a given area (represented by an arrow and black 
circle).  The coordinates of the alpha carbonyl of each known attacked carbon in the 
closed model are indicated by spheres (adrenorphin = dark pink, bradykinin = yellow, 
dynorphin A(1-8) = light blue, dynorphin A(1-13) = orange, dynorphin B(1-9) = green, 
neurotensin = light pink).  TOP side chains involved in catalysis are shown as stick 
models including His600, Tyr605, Tyr612, His473, Glu474, His477, and Glu502. 
 
 
 
 
(a) (b) 
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Figure 6.4  Alternative models for substrates during hinge closure. One of two 
models can be used to explain the registration of initial substrate binding.  a) during hinge 
closure some substrates lift off and change registration in the binding site b) during hinge 
closure domain I shifts carrying the substrate with it in the current registration. 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
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Figure 6.5  Proposed incorporation of drug into nano test tubes.  a) dissolve the drug 
in solvent and apply to alumina template b) non-destructive replication as usual c) after 
coating and sonication the drug will be suspended in aqueous solution and trapped inside 
nano test tubes. 
 
Copyright © Jonathan Wagner 2012 
150 
 
BIBLIOGRAPHY 
1. Shrimpton, C.N., A.I. Smith, and R.A. Lew, Soluble metalloendopeptidases and 
neuroendocrine signaling. Endocrine Reviews, 2002. 23(5): p. 647-664. 
2. Heise, T., et al., Pharmacokinetics, pharmacodynamics and tolerability of multiple oral 
doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. 
Diabetes Obesity & Metabolism, 2009. 11(8): p. 786-794. 
3. Garg, R. and S. Yusuf, OVERVIEW OF RANDOMIZED TRIALS OF ANGIOTENSIN-
CONVERTING ENZYME-INHIBITORS ON MORTALITY AND MORBIDITY IN PATIENTS WITH 
HEART-FAILURE. Jama-Journal of the American Medical Association, 1995. 273(18): p. 
1450-1456. 
4. Pitt, B., et al., The effect of spironolactone on morbidity and mortality in patients with 
severe heart failure. New England Journal of Medicine, 1999. 341(10): p. 709-717. 
5. Yusuf, S., et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on 
cardiovascular events in high-risk patients. New England Journal of Medicine, 2000. 
342(3): p. 145-153. 
6. Vincent, B., et al., Contribution of endopeptidase 3.4.24.15 to central neurotensin 
inactivation. European Journal of Pharmacology, 1997. 334(1): p. 49-53. 
7. Kest, B., M. Orlowski, and R.J. Bodnar, INCREASES IN OPIOID-MEDIATED SWIM 
ANTINOCICEPTION FOLLOWING ENDOPEPTIDASE-24.15 INHIBITION. Physiology & 
Behavior, 1991. 50(4): p. 843-845. 
8. Mentlein, R. and P. Dahms, ENDOPEPTIDASE-24.16 AND ENDOPEPTIDASE-24.15 ARE 
RESPONSIBLE FOR THE DEGRADATION OF SOMATOSTATIN, NEUROTENSIN, AND OTHER 
NEUROPEPTIDES BY CULTIVATED RAT CORTICAL ASTROCYTES. Journal of 
Neurochemistry, 1994. 62(1): p. 27-36. 
9. Molineaux, C.J. and J.M. Ayala, AN INHIBITOR OF ENDOPEPTIDASE-24.15 BLOCKS THE 
DEGRADATION OF INTRAVENTRICULARLY ADMINISTERED DYNORPHINS. Journal of 
Neurochemistry, 1990. 55(2): p. 611-618. 
10. Kim, S.I., et al., Novel roles of neuropeptide processing enzymes: EC3.4.24.15 in the 
neurome. Journal of Neuroscience Research, 2003. 74(3): p. 456-467. 
11. Genden, E.M. and C.J. Molineaux, INHIBITION OF ENDOPEPTIDASE-24.15 DECREASES 
BLOOD-PRESSURE IN NORMOTENSIVE RATS. Hypertension, 1991. 18(3): p. 360-365. 
12. Norman, M.U., et al., Regulation of cardiovascular signaling by kinins and products of 
similar converting enzyme systems - Endopeptidases 3.4.24.15 and 24.16 in endothelial 
cells: potential role in vasoactive peptide metabolism. American Journal of Physiology-
Heart and Circulatory Physiology, 2003. 284(6): p. H1978-H1984. 
13. Smith, A.I., et al., A novel stable inhibitor of endopeptidases EC 3.4.24.15 and 3.4.24.16 
potentiates bradykinin-induced hypotension. Hypertension, 2000. 35(2): p. 626-630. 
14. Kim, S.I., et al., Regulation of cell-surface major histocompatibility complex class I 
expression by the endopeptidase EC3.4.24.15 (thimet oligopeptidase). Biochem. J., 2003. 
375(Pt 1): p. 111-120. 
15. Saric, T., et al., Major histocompatibility complex class I-presented antigenic peptides are 
degraded in cytosolic extracts primarily by thimet oligopeptidase. Journal of Biological 
Chemistry, 2001. 276(39): p. 36474-36481. 
16. Portaro, F.C.V., et al., Thimet oligopeptidase and the stability of MHC class I epitopes in 
macrophage cytosol. Biochemical and Biophysical Research Communications, 1999. 
255(3): p. 596-601. 
151 
 
17. Molineaux, C.J., et al., ENDOPEPTIDASE-24.15 IS THE PRIMARY ENZYME THAT DEGRADES 
LUTEINIZING-HORMONE RELEASING HORMONE BOTH INVITRO AND INVIVO. Journal of 
Neurochemistry, 1988. 51(2): p. 624-633. 
18. Paschoalin, T., et al., Characterization of thimet oligopeptidase and neurolysin activities 
in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth. 
Molecular Cancer, 2007. 6. 
19. Yamin, R., et al., Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's 
amyloid-beta peptide degradation. Journal of Biological Chemistry, 1999. 274(26): p. 
18777-18784. 
20. Jiracek, J., et al., DEVELOPMENT OF HIGHLY POTENT AND SELECTIVE PHOSPHINIC 
PEPTIDE INHIBITORS OF ZINC ENDOPEPTIDASE-24-15 USING COMBINATORIAL 
CHEMISTRY. Journal of Biological Chemistry, 1995. 270(37): p. 21701-21706. 
21. Wilkins, M.R., R.J. Unwin, and A.J. Kenny, ENDOPEPTIDASE-24.11 AND ITS INHIBITORS - 
POTENTIAL THERAPEUTIC AGENTS FOR EDEMATOUS DISORDERS AND HYPERTENSION. 
Kidney International, 1993. 43(2): p. 273-285. 
22. Vincent, B., et al., PHOSPHORUS-CONTAINING PEPTIDES AS MIXED INHIBITORS OF 
ENDOPEPTIDASE-3.4.24.15 AND ENDOPEPTIDASE-3.4.24.16 - EFFECT ON NEUROTENSIN 
DEGRADATION IN-VITRO AND IN-VIVO. British Journal of Pharmacology, 1995. 115(6): p. 
1053-1063. 
23. Lim, E.J., et al., Swapping the substrate specificities of the neuropeptidases neurolysin 
and thimet oligopeptidase. Journal of Biological Chemistry, 2007. 282(13): p. 9722-9732. 
24. Checler, F., J.P. Vincent, and P. Kitabgi, PURIFICATION AND CHARACTERIZATION OF A 
NOVEL NEUROTENSIN-DEGRADING PEPTIDASE FROM RAT-BRAIN SYNAPTIC-
MEMBRANES. Journal of Biological Chemistry, 1986. 261(24): p. 1274-1281. 
25. Dahms, P. and R. Mentlein, PURIFICATION OF THE MAIN SOMATOSTATIN-DEGRADING 
PROTEASES FROM RAT AND PIG BRAINS, THEIR ACTION ON OTHER NEUROPEPTIDES, 
AND THEIR IDENTIFICATION AS ENDOPEPTIDASES 24.15 AND 24.16. European Journal of 
Biochemistry, 1992. 208(1): p. 145-154. 
26. Norman, M.U., et al., Regulation of cardiovascular signaling by kinins and products of 
similar converting enzyme systems - Metalloendopeptidases EC 3.4.24.15/16 regulate 
bradykinin activity in the cerebral microvasculature. American Journal of Physiology-
Heart and Circulatory Physiology, 2003. 284(6): p. H1942-H1948. 
27. Cleverly, K. and T.J. Wu, Is the metalloendopeptidase EC 3.4.24.15 (EP24.15), the enzyme 
that cleaves luteinizing hormone-releasing hormone (LHRH), an activating enzyme? 
Reproduction, 2010. 139(2): p. 319-330. 
28. Lasdun, A., et al., INHIBITION OF ENDOPEPTIDASE 24.15 SLOWS THE INVIVO 
DEGRADATION OF LUTEINIZING-HORMONE-RELEASING HORMONE. Journal of 
Pharmacology and Experimental Therapeutics, 1989. 251(2): p. 439-447. 
29. Lew, R.A., et al., EVIDENCE FOR A 2-STEP MECHANISM OF GONADOTROPIN-RELEASING-
HORMONE METABOLISM BY PROLYL ENDOPEPTIDASE AND METALLOENDOPEPTIDASE 
EC-3.4.24.15 IN OVINE HYPOTHALAMIC EXTRACTS. Journal of Biological Chemistry, 1994. 
269(17): p. 12626-12632. 
30. Acker, G.R., C. Molineaux, and M. Orlowski, SYNAPTOSOMAL MEMBRANE-BOUND FORM 
OF ENDOPEPTIDASE-24.15 GENERATES LEU-ENKEPHALIN FROM DYNORPHIN1-8, ALPHA-
NEUENDORPHIN-BETA-NEOENDORPHIN, AND MET-ENKEPHALIN FROM MET-
ENKEPHALIN-ARG6-GLY7-LEU8. Journal of Neurochemistry, 1987. 48(1): p. 284-292. 
31. Jiracek, J., et al., Development of the first potent and selective inhibitor of the zinc 
endopeptidase neurolysin using a systematic approach based on combinatorial 
152 
 
chemistry of phosphinic peptides. Journal of Biological Chemistry, 1996. 271(32): p. 
19606-19611. 
32. Shrimpton, C.N. and A.I. Smith, Soluble neutral metallopeptidases: Physiological 
regulators of peptide action. Journal of Peptide Science, 2000. 6(6): p. 251-263. 
33. Stadler, M., et al., Novel analgesic triglycerides from cultures of Agaricus macrosporus 
and other basidiomycetes as selective inhibitors of neurolysin. Journal of Antibiotics, 
2005. 58(12): p. 775-786. 
34. Orlowski, M., THE MULTICATALYTIC PROTEINASE COMPLEX, A MAJOR 
EXTRALYSOSOMAL PROTEOLYTIC SYSTEM. Biochemistry, 1990. 29(45): p. 10289-10297. 
35. Rock, K.L., et al., INHIBITORS OF THE PROTEASOME BLOCK THE DEGRADATION OF MOST 
CELL-PROTEINS AND THE GENERATION OF PEPTIDES PRESENTED ON MHC CLASS-I 
MOLECULES. Cell, 1994. 78(5): p. 761-771. 
36. Batalia, M.A. and E.J. Collins, Peptide binding by class I and class II MHC molecules. 
Biopolymers, 1997. 43(4): p. 281-302. 
37. Zhang, W.G., et al., CRYSTAL-STRUCTURE OF THE MAJOR HISTOCOMPATIBILITY 
COMPLEX CLASS-I H-2K(B) MOLECULE CONTAINING A SINGLE VIRAL PEPTIDE - 
IMPLICATIONS FOR PEPTIDE BINDING AND T-CELL RECEPTOR RECOGNITION. 
Proceedings of the National Academy of Sciences of the United States of America, 1992. 
89(17): p. 8403-8407. 
38. Matsumura, M., et al., EMERGING PRINCIPLES FOR THE RECOGNITION OF PEPTIDE 
ANTIGENS BY MHC CLASS-I MOLECULES. Science, 1992. 257(5072): p. 927-934. 
39. Madden, D.R., D.N. Garboczi, and D.C. Wiley, THE ANTIGENIC IDENTITY OF PEPTIDE-MHC 
COMPLEXES - A COMPARISON OF THE CONFORMATIONS OF 5 VIRAL PEPTIDES 
PRESENTED BY HLA-A2. Cell, 1993. 75(4): p. 693-708. 
40. Brown, J.H., et al., 3-DIMENSIONAL STRUCTURE OF THE HUMAN CLASS-II 
HISTOCOMPATIBILITY ANTIGEN HLA-DR1. Nature, 1993. 364(6432): p. 33-39. 
41. Stanfield, R.L. and I.A. Wilson, PROTEIN-PEPTIDE INTERACTIONS. Current Opinion in 
Structural Biology, 1995. 5(1): p. 103-113. 
42. Rothbard, J.B. and M.L. Gefter, INTERACTIONS BETWEEN IMMUNOGENIC PEPTIDES AND 
MHC PROTEINS. Annual Review of Immunology, 1991. 9: p. 527-565. 
43. Oliveira, V., et al., Substrate specificity characterization of recombinant metallo oligo-
peptidases thimet oligopeptidase and neurolysin. Biochemistry, 2001. 40(14): p. 4417-
4425. 
44. Knight, C.G., P.M. Dando, and A.J. Barrett, THIMET OLIGOPEPTIDASE SPECIFICITY - 
EVIDENCE OF PREFERENTIAL CLEAVAGE NEAR THE C-TERMINUS AND PRODUCT 
INHIBITION FROM KINETIC-ANALYSIS OF PEPTIDE HYDROLYSIS. Biochemical Journal, 
1995. 308: p. 145-150. 
45. Oliveira, V., et al., Temperature and salts effects on the peptidase activities of the 
recombinant metallooligopeptidases neurolysin and thimet oligopeptidase. European 
Journal of Biochemistry, 2002. 269(17): p. 4326-4334. 
46. Hooper, N.M., FAMILIES OF ZINC METALLOPROTEASES. Febs Letters, 1994. 354(1): p. 1-
6. 
47. Weaver, L.H., W.R. Kester, and B.W. Matthews, CRYSTALLOGRAPHIC STUDY OF 
COMPLEX OF PHOSPHORAMIDON WITH THERMOLYSIN - MODEL FOR PRESUMED 
CATALYTIC TRANSITION-STATE AND FOR BINDING OF EXTENDED SUBSTRATES. Journal of 
Molecular Biology, 1977. 114(1): p. 119-132. 
48. Matthews, B.W., et al., 3-DIMENSIONAL STRUCTURE OF THERMOLYSIN. Nature-New 
Biology, 1972. 238(80): p. 37-&. 
153 
 
49. Ray, K., et al., Crystal structure of human thimet oligopeptidase provides insight into 
substrate recognition, regulation, and localization. Journal of Biological Chemistry, 2004. 
279(19): p. 20480-20489. 
50. Brown, C.K., et al., Structure of neurolysin reveals a deep channel that limits substrate 
access. Proceedings of the National Academy of Sciences of the United States of 
America, 2001. 98(6): p. 3127-3132. 
51. Comellas-Bigier, M., et al., Crystal structure of the E-coli dipeptidyl carboxypeptidase 
Dcp: Further indication of a ligand-dependant hinge movement mechanism. Journal of 
Molecular Biology, 2005. 349(1): p. 99-112. 
52. Towler, P., et al., ACE2 X-ray structures reveal a large hinge-bending motion important 
for inhibitor binding and catalysis. Journal of Biological Chemistry, 2004. 279(17): p. 
17996-18007. 
53. Eng, C.M., et al., Safety and efficacy of recombinant human alpha-galactosidase a 
replacement therapy in Fabry's disease. New England Journal of Medicine, 2001. 345(1): 
p. 9-16. 
54. Leader, B., Q.J. Baca, and D.E. Golan, Protein therapeutics: A summary and 
pharmacological classification. Nature Reviews Drug Discovery, 2008. 7(1): p. 21-39. 
55. Trusheim, M., et al., Characterizing markets for biopharmaceutical innovations : do 
biologics differ from small molecules?2010, Cambridge, MA: National Bureau of 
Economic Research. 
56. Barton, N.W., et al., REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - 
MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE. New 
England Journal of Medicine, 1991. 324(21): p. 1464-1470. 
57. Weinreb, N.J., et al., Effectiveness of enzyme replacement therapy in 1028 patients with 
type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher 
Registry. American Journal of Medicine, 2002. 113(2): p. 112-119. 
58. Hirano, M., Recombinant enzyme replacement therapy for infantile-onset Pompe 
disease. Current Neurology and Neuroscience Reports, 2008. 8(1): p. 45-47. 
59. Burrow, T.A., et al., Enzyme reconstitution/replacement therapy for lysosomal storage 
diseases. Current Opinion in Pediatrics, 2007. 19(6): p. 628-635. 
60. Hansel, T.T., et al., The safety and side effects of monoclonal antibodies. Nature Reviews 
Drug Discovery, 2010. 9(4): p. 325-338. 
61. Liu, Y., et al., Circulating neprilysin clears brain amyloid. Molecular and Cellular 
Neuroscience, 2010. 45(2): p. 101-107. 
62. Liu, Y.X., et al., Expression of Neprilysin in Skeletal Muscle Reduces Amyloid Burden in a 
Transgenic Mouse Model of Alzheimer Disease. Molecular Therapy, 2009. 17(8): p. 1381-
1386. 
63. Young, L.S., et al., Viral gene therapy strategies: from basic science to clinical 
application. Journal of Pathology, 2006. 208(2): p. 299-318. 
64. De Vocht, C., et al., Assessment of stability, toxicity and immunogenicity of new 
polymeric nanoreactors for use in enzyme replacement therapy of MNGIE. Journal of 
Controlled Release, 2009. 137(3-4): p. 246-254. 
65. Kim, J.B., J.W. Grate, and P. Wang, Nanobiocatalysis and its potential applications. 
Trends in Biotechnology, 2008. 26(11): p. 639-646. 
66. Klibanov, A.M., Enzyme stabilization by immobilization. Analytical Biochemistry, 1979. 
93: p. 1-25. 
67. Kim, J., J.W. Grate, and P. Wang, Nanostructures for enzyme stabilization. Chemical 
Engineering Science, 2006. 61(3): p. 1017-1026. 
154 
 
68. Walde, P. and S. Ichikawa, Enzymes inside lipid vesicles: Preparation, reactivity and 
applications. Biomolecular Engineering, 2001. 18(4): p. 143-177. 
69. Hashemifard, N., et al., Fabrication and kinetic studies of a novel silver nanoparticles-
glucose oxidase bioconjugate. Analytica Chimica Acta, 2010. 675(2): p. 181-184. 
70. Aubin-Tam, M.E. and K. Hamad-Schifferli, Structure and function of nanoparticle-protein 
conjugates. Biomedical Materials, 2008. 3(3): p. 17. 
71. Herdt, A.R., B.S. Kim, and T.A. Taton, Encapsulated magnetic nanoparticles as supports 
for proteins and recyclable biocatalysts. Bioconjugate Chemistry, 2007. 18(1): p. 183-
189. 
72. Huang, S.H., M.H. Liao, and D.H. Chen, Direct binding and characterization of lipase onto 
magnetic nanoparticles. Biotechnology Progress, 2003. 19(3): p. 1095-1100. 
73. Medintz, I.L., et al., Quantum dot bioconjugates for imaging, labelling and sensing. 
Nature Materials, 2005. 4(6): p. 435-446. 
74. Gupta, A.K. and M. Gupta, Synthesis and surface engineering of iron oxide nanoparticles 
for biomedical applications. Biomaterials, 2005. 26(18): p. 3995-4021. 
75. Hsu, J., et al., Enhanced endothelial delivery and biochemical effects of alpha-
galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. Journal of Controlled 
Release, 2011. 149(3): p. 323-331. 
76. Bale, S.S., et al., Nanoparticle-Mediated Cytoplasmic Delivery of Proteins To Target 
Cellular Machinery. Acs Nano, 2010. 4(3): p. 1493-1500. 
77. Muro, S., New biotechnological and nanomedicine strategies for treatment of lysosomal 
storage disorders. Wiley Interdisciplinary Reviews-Nanomedicine and 
Nanobiotechnology, 2010. 2(2): p. 189-204. 
78. Ranquin, A., et al., Therapeutic nanoreactors: Combining chemistry and biology in a 
novel triblock copolymer drug delivery system. Nano Letters, 2005. 5(11): p. 2220-2224. 
79. Huysmans, G., et al., Encapsulation of therapeutic nucleoside hydrolase in functionalised 
nanocapsules. Journal of Controlled Release, 2005. 102(1): p. 171-179. 
80. Geng, Y., et al., Shape effects of filaments versus spherical particles in flow and drug 
delivery. Nature Nanotechnology, 2007. 2(4): p. 249-255. 
81. Hillebrenner, H., et al., Template synthesized nanotubes for biomedical delivery 
applications. Nanomedicine, 2006. 1(1): p. 39-50. 
82. Moghimi, S.M., A.C. Hunter, and J.C. Murray, Long-circulating and target-specific 
nanoparticles: Theory to practice. Pharmacological Reviews, 2001. 53(2): p. 283-318. 
83. Perry, J.L., et al., Fabrication of biodegradable nano test tubes by template synthesis. 
Nanomedicine, 2010. 5(8): p. 1151-1160. 
84. Perry, J.L., C.R. Martin, and J.D. Stewart, Drug-Delivery Strategies by Using Template-
Synthesized Nanotubes. Chemistry-a European Journal, 2011. 17(23): p. 6296-6302. 
85. Son, S.J., et al., Magnetic nanotubes for magnetic-field-assisted bioseparation, 
biointeraction, and drug delivery. Journal of the American Chemical Society, 2005. 
127(20): p. 7316-7317. 
86. Masuda, H. and K. Fukuda, ORDERED METAL NANOHOLE ARRAYS MADE BY A 2-STEP 
REPLICATION OF HONEYCOMB STRUCTURES OF ANODIC ALUMINA. Science, 1995. 
268(5216): p. 1466-1468. 
87. Gasparac, R., et al., Template synthesis of nano test tubes. Nano Letters, 2004. 4(3): p. 
513-516. 
88. Grimm, S., et al., Nondestructive replication of self-ordered nanoporous alumina 
membranes via cross-linked polyacrylate nanofiber arrays. Nano Letters, 2008. 8(7): p. 
1954-1959. 
155 
 
89. Choi, M.K., et al., Simple Fabrication of Asymmetric High-Aspect-Ratio Polymer 
Nanopillars by Reusable AAO Templates. Langmuir, 2011. 27(6): p. 2132-2137. 
90. Oliveira, V., et al., Selective Neurotensin-Derived Internally Quenched Fluorogenic 
Substrates for Neurolysin (EC 3.4.24.16): Comparison with Thimet Oligopeptidase (EC 
3.4.24.15) and Neprilysin (EC 3.4.24.11). Analytical Biochemistry, 2001. 292(2): p. 257-
265. 
91. Peters, K. and F.M. Richards, CHEMICAL CROSS-LINKING - REAGENTS AND PROBLEMS IN 
STUDIES OF MEMBRANE STRUCTURE. Annual Review of Biochemistry, 1977. 46: p. 523-
551. 
92. Quiocho, F.A. and F.M. Richards, INTERMOLECULAR CROSS LINKING OF PROTEIN IN 
CRYSTALLINE STATE - CARBOXYPEPTIDASE-A. Proceedings of the National Academy of 
Sciences of the United States of America, 1964. 52(3): p. 833-&. 
93. Rodgers, D.W., Practical cryocrystallography. Macromolecular Crystallography, Pt A, 
1997. 276: p. 183-203. 
94. Otwinowski, Z. and W. Minor, Processing of X-ray diffraction data collected in oscillation 
mode. Macromolecular Crystallography, Pt A, 1997. 276: p. 307-326. 
95. McCoy, A.J., et al., Likelihood-enhanced fast translation functions. Acta Crystallographica 
Section D-Biological Crystallography, 2005. 61: p. 458-464. 
96. Storoni, L.C., A.J. McCoy, and R.J. Read, Likelihood-enhanced fast rotation functions. 
Acta Crystallographica Section D-Biological Crystallography, 2004. 60: p. 432-438. 
97. Adams, P.D., et al., PHENIX: building new software for automated crystallographic 
structure determination. Acta Crystallographica Section D-Biological Crystallography, 
2002. 58: p. 1948-1954. 
98. Emsley, P. and K. Cowtan, Coot: model-building tools for molecular graphics. Acta 
Crystallographica Section D-Biological Crystallography, 2004. 60: p. 2126-2132. 
99. Wiseman, T., et al., RAPID MEASUREMENT OF BINDING CONSTANTS AND HEATS OF 
BINDING USING A NEW TITRATION CALORIMETER. Analytical Biochemistry, 1989. 
179(1): p. 131-137. 
100. Freyer, M.W. and E.A. Lewis, Isothermal titration calorimetry: Experimental design, data 
analysis, and probing Macromolecule/Ligand binding and kinetic interactions, in 
Biophysical Tools for Biologists: Vol 1 in Vitro Techniques2008, Elsevier Academic Press 
Inc: San Diego. p. 79-113. 
101. ExPASy - ProtParam tool. 2012; Available from: 
http://www.expasy.org/tools/protparam.html. 
102. Sadasivan, V., et al., Electrochemical self-assembly of porous alumina templates. Aiche 
Journal, 2005. 51(2): p. 649-655. 
103. Microplate Dimensions Guide, in www.gbo.com/bioscience2007, Greiner. 
104. Noinaj, N., Structural Insights into the Substrate recognition and Catalytic Mechanism of 
Thimet Oligopeptidase and the Activation and Allosteric Regulation of Insulysin, in 
Molecular and Cellular Biochemistry2008, University of Kentucky: Lexington. p. 183. 
105. Rioli, V., et al., Neuropeptide specificity and inhibition of recombinant isoforms of the 
endopeptidase 3.4.24.16 family: Comparison with the related recombinant 
endopeptidase 3.4.24.15. Biochemical and Biophysical Research Communications, 1998. 
250(1): p. 5-11. 
106. Rodd, D. and L.B. Hersh, ENDOPEPTIDASE-24.16B - A NEW VARIANT OF 
ENDOPEPTIDASE-24.16. Journal of Biological Chemistry, 1995. 270(17): p. 10056-10061. 
156 
 
107. Lew, R.A., et al., Evidence for a two-step mechanism of GnRH metabolism by prolyl 
endopeptidase and metalloendopeptidase EC 3.4.24.15. Society for Neuroscience 
Abstracts, 1993. 19(1-3): p. 1069. 
108. Berti, D.A., et al., Analysis of Intracellular Substrates and Products of Thimet 
Oligopeptidase in Human Embryonic Kidney 293 Cells. Journal of Biological Chemistry, 
2009. 284(21): p. 14105-14116. 
109. Rioli, V., et al., Novel natural peptide substrates for endopeptidase 24.15, neurolysin, 
and angiotensin-converting enzyme. Journal of Biological Chemistry, 2003. 278(10): p. 
8547-8555. 
110. Camargo, A.C.M., et al., Structural features that make oligopeptides susceptible 
substrates for hydrolysis by recombinant thimet oligopeptidase. Biochemical Journal, 
1997. 324: p. 517-522. 
111. Lew, R.A., et al., SUBSTRATE-SPECIFICITY DIFFERENCES BETWEEN RECOMBINANT RAT 
TESTES ENDOPEPTIDASE EC-3.4.24.15 AND THE NATIVE BRAIN ENZYME. Biochemical and 
Biophysical Research Communications, 1995. 209(3): p. 788-795. 
112. Reed, B., et al., Dynorphin B biotransformation in the striatum of freely-moving rats: 
Microdialysis and mass spectrometry. Society for Neuroscience Abstract Viewer and 
Itinerary Planner, 2003. 2003: p. Abstract No. 645.17. 
113. Kilpatrick, D.L., et al., CHARACTERIZATION OF RIMORPHIN, A NEW LEU ENKEPHALIN-
CONTAINING PEPTIDE FROM BOVINE POSTERIOR PITUITARY-GLANDS. Life Sciences, 
1982. 31(16-1): p. 1849-1852. 
114. Holland, D.R., et al., STRUCTURAL COMPARISON SUGGESTS THAT THERMOLYSIN AND 
RELATED NEUTRAL PROTEASES UNDERGO HINGE-BENDING MOTION DURING 
CATALYSIS. Biochemistry, 1992. 31(46). 
115. Bruce, L.A., et al., Hydrogen bond residue positioning in the 599-611 loop of thimet 
oligopeptidase is required for substrate selection. Febs Journal, 2008. 275(22): p. 5607-
5617. 
116. Machado, M.F.M., et al., The role of Tyr(605) and Ala(607) of thimet oligopeptidase and 
Tyr(606) and Gly(608) of neurolysin in substrate hydrolysis and inhibitor binding. 
Biochemical Journal, 2007. 404: p. 279-288. 
117. Kawasaki, A., et al., The Exquisite Structure and Reaction Mechanism of Bacterial Pz-
peptidase A toward Collagenous Peptides X-RAY CRYSTALLOGRAPHIC STRUCTURE 
ANALYSIS OF PZ-PEPTIDASE A REVEALS DIFFERENCES FROM MAMMALIAN THIMET 
OLIGOPEPTIDASE. Journal of Biological Chemistry. 285(45): p. 34972-34980. 
118. Schechter, I. and A. Berger, On the size of the active site in proteases. I. Papain. Biochem 
Biophys Res Commun, 1967. 27(2): p. 157-62. 
119. Hines, C.S., Crystallographic and Functional Studies on the Neuropeptidase Neurolysin, in 
Biochemistry2003, University of Kentucky: Lexington. 
120. Rammensee, H.G., K. Falk, and O. Rotzschke, PEPTIDES NATURALLY PRESENTED BY MHC 
CLASS-I MOLECULES. Annual Review of Immunology, 1993. 11: p. 213-244. 
121. Carroll, M.J., et al., Evidence for dynamics in proteins as a mechanism for ligand 
dissociation. Nature Chemical Biology, 2012. 8(3): p. 246-252. 
122. Kato, A., et al., CLONING, AMINO-ACID-SEQUENCE AND TISSUE DISTRIBUTION OF 
PORCINE THIMET OLIGOPEPTIDASE - A COMPARISON WITH SOLUBLE ANGIOTENSIN-
BINDING PROTEIN. European Journal of Biochemistry, 1994. 221(1): p. 159-165. 
123. McKie, N., et al., THIMET OLIGOPEPTIDASE - SIMILARITY TO SOLUBLE ANGIOTENSIN II-
BINDING PROTEIN AND SOME CORRECTIONS TO THE PUBLISHED AMINO-ACID-
SEQUENCE OF THE RAT TESTIS ENZYME. Biochemical Journal, 1993. 295: p. 57-60. 
157 
 
124. Wangler, N.J., et al., Identification of Membrane-bound Variant of 
Metalloendopeptidase Neurolysin (EC 3.4.24.16) as the Non-angiotensin Type 1 (Non-
AT1), Non-AT(2) Angiotensin Binding Site. Journal of Biological Chemistry, 2012. 287(1): 
p. 114-122. 
125. Orlowski, M., et al., Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its 
specificity toward synthetic and natural peptides, including enkephalin-containing 
peptides. Biochem. J., 1989. 261(3): p. 951-958. 
126. Goldberg, R.N., N. Kishore, and R.M. Lennen, Thermodynamic quantities for the 
ionization reactions of buffers. Journal of Physical and Chemical Reference Data, 2002. 
31(2): p. 231-370. 
127. Li, H., A.D. Robertson, and J.H. Jensen, Very fast empirical prediction and rationalization 
of protein pK(a) values. Proteins-Structure Function and Bioinformatics, 2005. 61(4): p. 
704-721. 
128. Ladbury, J.E., Application of isothermal titration calorirnetry in the biological sciences: 
Things are heating up! Biotechniques, 2004. 37(6): p. 885-887. 
129. Vallee, B.L. and D.S. Auld, ZINC - BIOLOGICAL FUNCTIONS AND COORDINATION MOTIFS. 
Accounts of Chemical Research, 1993. 26(10): p. 543-551. 
130. Natesh, R., et al., Crystal structure of the human angiotensin-converting enzyme-
lisinopril complex. Nature, 2003. 421(6922): p. 551-554. 
131. O'Sullivan, P.L., F.H. Baumann, and G.H. Gilmer, Simulation of physical vapor deposition 
into trenches and vias: Validation and comparison with experiment. Journal of Applied 
Physics, 2000. 88(7): p. 4061-4068. 
132. Dew, S., T. Smy, and M. Brett, STEP COVERAGE, UNIFORMITY AND COMPOSITION 
STUDIES USING INTEGRATED VAPOR TRANSPORT AND FILM-DEPOSITION MODELS. 
Japanese Journal of Applied Physics Part 1-Regular Papers Short Notes & Review Papers, 
1994. 33(2): p. 1140-1145. 
133. Okuyama, T., et al., Japan Elaprase (R) Treatment (JET) study: Idursulfase enzyme 
replacement therapy in adult patients with attenuated Hunter syndrome 
(Mucopolysaccharidosis II, MPS II). Molecular Genetics and Metabolism, 2010. 99(1): p. 
18-25. 
134. Murphy, C.J., et al., Gold Nanoparticles in Biology: Beyond Toxicity to Cellular Imaging. 
Accounts of Chemical Research, 2008. 41(12): p. 1721-1730. 
135. Hermanson, G., Bioconjugate Techniques1996: Academic Press. 
136. Czapinska, H. and J. Otlewski, Structural and energetic determinants of the S-1-site 
specificity in serine proteases. European Journal of Biochemistry, 1999. 260(3): p. 571-
595. 
137. Lovejoy, B., et al., Crystal structures of MMP-1 and -13 reveal the structural basis for 
selectivity of collagenase inhibitors. Nature Structural Biology, 1999. 6(3): p. 217-221. 
138. Perona, J.J. and C.S. Craik, Evolutionary divergence of substrate specificity within the 
chymotrypsin-like serine protease fold. Journal of Biological Chemistry, 1997. 272(48): p. 
29987-29990. 
139. Gomis-Ruth, F.X., Structure and Mechanism of Metallocarboxypeptidases. Critical 
Reviews in Biochemistry and Molecular Biology, 2008. 43(5): p. 319-345. 
140. Ramagopal U.A, T.R., Meyer A.J., Freeman J., Bain K., Rodgers L., Sauder J.M., Burley 
S.K., Almo S.C., Crystal structure of oligoendopeptidase-F from Enterococcus faecium., 
2007. 
141. Li, F., et al., Structure of SARS coronavirus spike receptor-binding domain complexed with 
receptor. Science, 2005. 309(5742): p. 1864-1868. 
158 
 
142. Niemirowicz, G., et al., The molecular analysis of Trypanosoma cruzi 
metallocarboxypeptidase 1 provides insight into fold and substrate specificity. Molecular 
Microbiology, 2008. 70(4): p. 853-866. 
143. Saric, T., C.I. Graef, and A.L. Goldberg, Pathway for degradation of peptides generated 
by proteasomes - A key role for thimet oligopeptidase and other metallopeptidases. 
Journal of Biological Chemistry, 2004. 279(45): p. 46723-46732. 
144. Silva, C.L., et al., Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of 
MHC class I antigen presentation. Biochemical and Biophysical Research 
Communications, 1999. 255(3): p. 591-595. 
145. Rock, K.L., I.A. York, and A.L. Goldberg, Post-proteasomal antigen processing for major 
histocompatibility complex class I presentation. Nature Immunology, 2004. 5(7): p. 670-
677. 
146. Hagiwara, H., et al., PURIFICATION AND CHARACTERIZATION OF ANGIOTENSIN-BINDING 
PROTEIN FROM PORCINE LIVER CYTOSOLIC FRACTION. European Journal of 
Biochemistry, 1989. 185(2): p. 405-410. 
147. Pelmenschikov, V., M.R.A. Blomberg, and P.E. Siegbahn, A theoretical study of the 
mechanism for peptide hydrolysis by thermolysin. Journal of Biological Inorganic 
Chemistry, 2002. 7(3): p. 284-298. 
148. Machado, M.F.M., et al., Catalytic properties of thimet oligopeptidase H600A mutant. 
Biochemical and Biophysical Research Communications. 394(2): p. 429-433. 
149. Muller, R.H., C. Jacobs, and O. Kayser, Nanosuspensions as particulate drug formulations 
in therapy Rationale for development and what we can expect for the future. Advanced 
Drug Delivery Reviews, 2001. 47(1): p. 3-19. 
150. Stegemann, S., et al., When poor solubility becomes an issue: From early stage to proof 
of concept. European Journal of Pharmaceutical Sciences, 2007. 31(5): p. 249-261. 
 
 
 
 
 
 
 
 
 
159 
 
 
VITA 
  
Jonathan Mark Wagner 
DOB  05/08/1983 
EDUCATION    
B.S. 
Biochemistry 
 
Southern Adventist University 
Chemistry Department 
2002 - 2006 
 
 
PUBLICATIONS  
in review: 
Wagner, J.M., Jingyuan, Y., Rodgers, D.W, Hinds B.J.  “Template synthesis of test tube 
nanoparticles using non-destructive replication”  
in preparation: 
Wagner, J.M., Noinaj, N., Rodgers, D.W.  “An unusual mechanism for broad substrate 
recognition found in a peptidase.”  
 
CONFERENCES / WORKSHOPS   
“X-ray Methods in Structural Biology”  Cold Springs Harbor, NY 2011 
American Society for Biochemistry and Molecular 
Biology (ASBMB) Annual Meeting 
New Orleans, LA 2009 
 
ORAL PRESENTATIONS   
“Neuropeptidase substrate recognition and 
therapeutic enzyme delivery.”  
Department of Biochemistry 
Student Seminar 
2011 
“Substrate Recognition and Therapeutic 
Applications of Neuropeptidases.”  
Department of Biochemistry 
Spring Retreat 
2011 
 
 
 
 
160 
 
POSTER PRESENTATIONS   
“Basis for Substrate Recognition and 
Therapeutic Delivery of 
Neuropeptidases.”  
Biochemistry Department Spring 
Retreat 
06/2012 
 “Encapsulation and Structure/Function  
  of Thimet Oligopeptidase.”  
38th Annual Naff Symposium 05/2012 
 “Substrate Recognition by Thimet  
  Oligopeptidase”  
9th Annual SER-CAT Symposium 03/2012 
   
 “Substrate Recognition and  
  Therapeutic Applications of  
  Neuropeptidases.”  
Biochemistry Department Spring 
Retreat 
05/2011 
   
“Encapsulation and Structure/Function  
  of Thimet Oligopeptidase”  
NSF Research Experience for 
Undergraduates (REU) 
06/2010 
   
“Encapsulation and Structure/Function 
  of Thimet Oligopeptidase”  
Biochemistry Department Spring 
Retreat 
05/2010 
   
 “Structure and Function of Thimet 
   Oligopeptidase”  
Biochemistry Department Spring 
Retreat 
05/2009 
   
 “Structure and Function of Thimet 
   Oligopeptidase”  
American Society for Biochemistry 
and Molecular Biology (ASBMB) 
Annual Meeting 
04/2009 
 
AWARDS   
NSF IGERT Fellowship University of Kentucky 2009-2011 
Daniel R. Reedy Award University of Kentucky 2007-2010 
STAR Scholarship  Southern Adventist University 2003-2006 
Presidential Scholarship Southern Adventist University 2002 
 
 
 
